



6TH
SYSTEMIC
SCLEROSIS
WORLD
E-CONGRESS

JULY **12-14**, 2020

www.worldsclerofound.org

TABLE OF CONTENTS

COMMITTEES pag. 3

CONGRESS FORMAT pag. 5

MEET THE PROFESSORS pag. 6

RECORDED PRESENTATIONS pag. 8

LIVE CONGRESS pag. 14

LIVE SATELLITE SYMPOSIA pag. 23

POSTER SESSION pag. 27

ACKNOWLEDGEMENTS pag. 47

COMMITTEES

Honorary Presidents

C Black, A Tyndall, F Wollheim, T Medsger

Steering Committee

DE Furst, T Krieg, M Matucci-Cerinic, K Takehara, O Distler, Y Allanore, M, Kuwana, D Khanna, J Seibold, C Denton

- *EULAR Liaison*: U Mueller-Ladner
- *Chairs of Mentoring Programme*: L Czirjak, M Mayes
- *Chair of Workshops*: P Clements
- *Fesca President*: S Farrington

Chair of the Scientific Programme Committee

Y Allanore

Co-Chairs of the Abstract Committee

Y Asano, S Assassi

Scientific Committee

D Abraham, J Avouac, A Balbir-Gurmann, M Baron, L Beretta, S Bosello, P Carreira, I Castellvi, C Chizzolini, L Chung, M Cutolo, N Damjanov, F Del Galdo, J Distler, C Feghali-Botswick, T Frech, A Gabrielli, S Guiducci, E Hachulla, A Herrick, M Hinchcliff, A Hoffmann-Vold, L Hummers, N Hunzelmann, M Inanc, S Johnson, JB Jun, S Kafaja, B Kahaleh, C Kayser, Y Kawaguchi, O Kowal-Bielecka, R Lafyatis, D Launay, EB Lee, Y Levy, MT Li, T Matsushita, B Maurer, C Mihai, L Mouthon, V Nagaraja, M Nikpour, J Noude Teclessou, J Pauling, J Pope, S Proudman, G Riemekasten, P Sampaio Barros, R Silver, V Smith, K Solanki, Y Suliman, M Tikly, ME Truchetet, F van den Hoogen, J van Laar, J Varga, E Volkmann, M Vonk, U Walker, J Wang, Y Wang, H Yasuoka, X Zeng

EARLY DIAGNOSIS AND TREATMENT INITIATION

MODERN PATIENT MANAGEMENT IN SSc-PAH

MONDAY 13th JULY 13:30 – 15:00 | CO-CHAIRS: Pavel Jansa and Marco Matucci

13:30 – 13:40	Welcome and introduction	Pavel Jansa
13:40 – 13:52	Screening for PAH in patients with SSc	Dinesh Khanna
13:52 – 14:04	Early and correct diagnosis of PAH is key in patients with SSc	Eric Hachulla
14:04 – 14:16	Assessing risk to make timely treatment decisions	Sean Gaine
14:16 – 14:30	Treatment strategies in SSc-PAH: Clinical evidence and the patient perspective	Janet Pope
14:30 – 14:50	Panel discussion and audience questions	All
14:50 – 15:00	Key messages and closing remarks	Marco Matucci-Cerinic

FACULTY

DINESH KHANNA
University of Michigan | Ann Arbor, USA

ERIC HACHULLA
University of Lille | Lille, France

SEAN GAINE
Mater Misericordiae University Hospital | Dublin, Ireland

JANET POPE
St. Joseph's Health Care London | London, Canada

CONGRESS FORMAT

CONGRESS SESSIONS

The presentations of the congress sessions will not run during the live congress days, they will be recorded and will be available in a dedicated section on the E-Congress platform (RECORDED SESSIONS) for participants' viewing starting **from June 29, until December 20, 2020**.

During the viewing, participants may submit written questions which will be evaluated by the speaker and moderators and possibly discussed during the live Discussion Sessions.

Questions will be possible until **July 7 included**.

Sessions 1, 2 and 3 will only be recorded and not discussed, therefore questions will not be possible.

PRE-CONGRESS WORKSHOPS

After the adaption of the scientific programme into the virtual format, unfortunately Pre-Congress workshops have been cancelled.

MEET THE PROFESSORS

Meet the Professors will be organized **on July 11 from 14:30 to 15:30 CEST**, only for participants previously registered. Attendees will receive the access link by email few days earlier.

SATELLITE SYMPOSIA

Most of Satellite Symposia will run live during the congress days as indicated in the programme, otherwise will be pre-recorded.

3-DAYS LIVE E-CONGRESS - July 12,13 and 14

During the three live congress days, presentations will only be discussed in the Live Discussion Sessions with the available speakers, according to the live E-Congress programme. Live chat questions will be possible during live discussions.

Please indicate the name of the speaker before the question (**@ + name of the speaker + question**).

Discussion sessions will be repeated twice along the three days, possibly with same questions.

Live E-Congress programme will run on Central European Summer Time (CEST).

The live congress days will be recorded and available in the "ON DEMAND" section **until December 20, 2020**.

POSTER PRESENTATIONS

Posters will be charged into the platform at disposal for all participants.

Authors will have at disposal a 3-minutes recording speech to be integrated to the poster file.

MEET THE PROFESSORS

The following Meet the Professor sessions will be organized as webinar **on July 11 from 14:30 to 15:30** Central European Summer Time (CEST) only for participants previously registered.

Participants will receive the technical information to attend the reserved session few days before the session will take place.

HOW TO MANAGE EARLY DCSSC

M Mayes (USA), J Pope (CA)

SRC

V Steen (USA)

SKIN BEYOND FIBROSIS

T Krieg (DE)



Boehringer Ingelheim kindly invites you to a satellite symposium:

New Paradigms in The Management of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Pre-recorded presentations available from Monday 13 July. Live questions and answers session to take place between 13:30 and 14:00 CEST on Tuesday 14 July.

During this symposium, an expert faculty will examine the latest evidence regarding the course of SSc-ILD and risk factors for progression and mortality, consider best practice in screening for and monitoring SSc-ILD, and discuss when treatment for SSc-ILD should be initiated.

Agenda

Chair: Oliver Distler

	Presentation	Speaker
10 mins	Welcome and introduction (pre-recorded)	Oliver Distler
20 mins	Natural course of SSc-ILD: what do we know? (pre-recorded)	Madelon Vank
20 mins	Treatment of SSc-ILD: whom and when? (pre-recorded)	Dinesh Khanna
30 mins	Questions and answers (live)	All

Medical Education with Boehringer Ingelheim

Session and speakers sponsored by Boehringer Ingelheim.

RECORDED PRESENTATIONS

The following presentations of the congress sessions will not run during the live congress days, they will be recorded and will be available in a dedicated section on the E-Congress platform (RECORDED PRESENTATIONS) for participants' viewing starting **from June 29, until December 20, 2020**.
Satellite Symposia will run live only except where indicated.

During the viewing, participants may submit written questions which will be evaluated by the speaker and moderators and possibly discussed during the live Discussion Sessions.

Questions will be possible until July 7 included.

Questions for presentations of speakers who will not attend the live Discussion Sessions will not be possible.

Sessions 1, 2 and 3 will only be recorded and not discussed, therefore questions will not be possible.

FROM JUNE 29

SATELLITE SYMPOSIA (see programmes at page 23)

Only recorded session

BOEHRINGER INGELHEIM SATELLITE SYMPOSIUM

Recorded presentations on platform from July 13 in the RECORDED PRESENTATIONS and "ON DEMAND" sections.

Live discussion of the symposium on July 14

Only live sessions

ACTELION SATELLITE SYMPOSIUM - live on July 13

CLS SATELLITE SYMPOSIUM - live on July 14

CORBUS SATELLITE SYMPOSIUM - live on July 12

MSD/BAYER SATELLITE SYMPOSIUM - live on July 12

SANOFI SATELLITE SYMPOSIUM - live on July 13

CONGRESS SESSIONS

SESSION 1 - OPENING LECTURES

Two years in review, basic
C Feghali-Botswick (USA)

Two years in review, clinical
C Denton (UK)

NO DISCUSSION at live congress, no questions

SESSION 2 - WSF/ASF PROJECTS

DEVELOPMENT OF THE OPTIMAL TOUCHSCREEN INTERFACE FOR PATIENTS WITH SCLERODERMA

G Moroncini et al (IT)

RANDOMIZED CONTROLLED TRIAL OF AN INTERNET-BASED EXERCISE PROGRAM TO IMPROVE HAND FUNCTION IN PATIENTS WITH SCLERODERMA: A SCLERODERMA PATIENT- CENTERED INTERVENTION NETWORK (SPIN) STUDY

L Kwakkenbos et al (NL)

"I'VE HANDED BACK MY MAN CARD": EXPERIENCES, COPING STYLES, AND SUPPORT PREFERENCES OF MEN WITH SSC

C Flurey et al (UK)

NO DISCUSSION at live congress, no questions

SESSION 3 - TAKEHARA'S PRIZE

UNRAVELLING THE AETIOPATHOGENESIS OF MORPHEA BY NEXT GENERATION SEQUENCING OF PAIRED SKIN BIOPSIES

AM Saracino et al (UK)

NO DISCUSSION at live congress, no questions

SESSION 4 - PULMONARY

How to screen and follow up SSc-ILD?

A Prasse (DE)

Group 3 PH, to treat or no to treat?

S Gaine (IE)

"IMAGES ARE MORE THAN PICTURES, THEY ARE DATA" - EXPLORATION OF RADIOMICS ANALYSIS FOR SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE

J Schniering et al (CH)

DISEASE COURSE OF PROGRESSIVE INTERSTITIAL LUNG DISEASE IN SSC: A 5-YEAR FOLLOW-UP FROM THE EUSTAR DATABASE

A Hoffmann-Vold et al (NO)

NEW HEMODYNAMIC DEFINITIONS OF PULMONARY HYPERTENSION: IS IT USEFUL IN SSC PATIENTS?

A Volkov et al (RU)

VEGF-C AND ITS RECEPTOR VEGFR-3 AS POTENTIAL SERUM BIOMARKERS FOR PULMONARY ARTERIAL HYPERTENSION IN SSC

H Didriksen et al (NO)

Discussion at live congress:

Sunday, July 12 - 09:30-10:00

and Monday, July 13 - 17:00-17:30

SESSION 5 - HEART

Screening for myocardial disease in SSc: which tools and when?

C Bucciarelli-Ducci (UK)

Cardiac work-up in SSc: how to distinguish primary heart involvement from ordinary cardiovascular disease

M Buch (UK)

SERUM CARDIAC BIOMARKERS AND CARDIAC MRI DIFFUSE FIBROSIS MAY PREDICT THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN SYSTEMIC SCLEROSIS PATIENTS

B Dumitru Raluca et al (UK)

SSC MYOCARDITIS HAS UNIQUE CLINICAL, HISTOLOGICAL AND PROGNOSTIC FEATURES: COMPARATIVE ANALYSIS BETWEEN PATIENTS WITH ENDOMYOCARDIAL BIOPSY-PROVEN MYOCARDITIS

G De Luca et al (IT)

PRIMARY SYSTEMIC SCLEROSIS HEART INVOLVEMENT (PSSCHI): A SYSTEMATIC LITERATURE REVIEW (SLR) AND PRELIMINARY CONSENSUS-BASED DEFINITION

C Bruni et al (IT)

Discussion at live congress:

Sunday, July 12 - 10:00-10:30

and Monday, July 13 - 17:30-18:00

SESSION 6 - SPECIAL SYMPOSIUM HIGHLIGHTS IN SSC RESEARCH ACROSS JOURNALS: CONTRIBUTION FROM THE RECENT LITERATURE

Journal Scleroderma & Rel Dis

Adipose-derived mesenchymal stromal/stem cells in systemic sclerosis: Alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1

S Hoffman (USA)

Lancet Rheumatology

Evidence-based consensus statements for the identification and management of interstitial lung disease in systemic sclerosis

A Hoffmann-Vold (NO)

Lancet Respiratory Medicine

Nintedanib in patients with progressive fibrosing interstitial lung diseases: subgroup analyses by interstitial lung disease diagnosis in the randomised, placebo-controlled INBUILD trial

A Wells (UK)

Arthritis & Rheumatology

The best highlights from A&R in 2019

J Varga (USA)

Discussion at live congress:

Sunday, July 12 - 11:45-12:15

and Monday, July 13 - 16:30-17:00

SESSION 7 - HORIZON 2020 THE BEST FROM THE DESSCIPHER PROJECT

Introduction into the desscipher Project

U Mueller-Ladner (DE)

Activity Indices and individualized Immunosuppression

V Lorand (H)

Functional Disability and Digital Ulcers

V Jaeger (DE)

Myocardium & Summary

U Mueller-Ladner (DE)

Discussion at live congress:

Sunday, July 12 - 10:30-10:45

and Monday, July 13 - 18:00-18:15

SESSION 8 - BASIC SESSION I*

Can tissue transcriptome be used for patients stratification?

F Del Galdo (UK)

Update on circulating Biomarkers

M. Kuwana (JP)

MACHINE-LEARNING CLASSIFICATION IN THE ABATACEPT IN SYSTEMIC SCLEROSIS TRIAL (ASSET) IDENTIFIES A SUBSET OF PATIENTS THAT IMPROVE ON THERAPY VIA MODULATION OF A CD28-RELATED PATHWAY

M Whitfield et al (USA)

LARGE-SCALE EXAMINATION OF LONGITUDINAL SKIN GENE EXPRESSION AND ITS ASSOCIATIONS WITH SKIN THICKNESS IN SSC

B Skaug et al (USA)

SERUM INTERFERON SCORE PREDICTS WORSE CLINICAL OUTCOME AT 12 MONTHS IN DIFFUSE SSC AS MEASURED BY GLOBAL RANKED COMPOSITE SCORE (GRCS) AND ACR COMPOSITE RESPONSE INDEX IN SSC (CRISS)

F Del Galdo et al (UK)

INTERFERON CHEMOKINE SCORE PREDICTS RESPONSE TO TREATMENT IN SSC RELATED INTERSTITIAL LUNG DISEASE

S Assassi et al (USA)

Discussion at live congress:

Sunday, July 12 - 11:15-11:45

and Monday, July 13 - 16:00-16:30

SESSION 9 - VASCULAR

Updated Algorithm in managing DU including combination therapy

M Matucci-Cerinic (IT)

PERFORMANCE OF AUTOMATED NAILFOLD CAPILLARY COUNTING SYSTEM (AUTOCAP) IN SSC PATIENTS

A Sulli et al (IT)

POTENTIAL BENEFICIAL EFFECTS FOR RESVERATROL IN SCLERODERMA VASCULOPATHY

B Kahaleh et al (USA)

ILOPROST USE AND MANAGEMENT OF SSC -RELATED VASCULOPATHY IN ITALIAN TERTIARY REFERRAL CENTERS: RESULTS FROM THE PROSIT STUDY

S Negrini et al (IT)

Discussion at live congress:

Sunday, July 12 - 10:45-11:15

and Tuesday, July 14 - 15:15-15:45

SESSION 10 - FREE CLINICAL PRESENTATIONS

PROVISIONAL AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) COMBINED RESPONSE INDEX IN DIFFUSE CUTANEOUS SSC (CRISS) SCORE CORRELATES WITH CHANGES <DELTA> IN PATIENT-REPORTED OUTCOMES (PRO)

R Spiera et al (USA)

THE EFFECT OF GENDER ON OUTCOME IN SSC: DOES ANTI-TOPOISOMERASE I AUTOANTIBODY (ATA) MATTER?

J De Vries-Bouwstra et al (NL)

THE PATIENT JOURNEY OF SSC-ILD IN EUROPE: AN INTEGRATED ANALYSIS OF HEALTHCARE PROFESSIONAL AND PATIENT PERSPECTIVES

A Hoffmann-Vold et al (NO)

THE TIMELINESS AND TYPES OF CANCER IN SSC

K Gunnarsson (SE)

THE RELATIONSHIP BETWEEN GASTROINTESTINAL SEVERITY AND SYMPTOMS AND WHOLE GUT TRANSIT IN PATIENTS WITH SSC

Z McMahan et al (USA)

VALIDATION OF DISEASE ACTIVITY MEASURES IN PATIENTS WITH JSSC - RESULTS FROM THE JSSC INCEPTION COHORT

I Foeldvari et al (DE)

Discussion at live congress:

Sunday, July 12 - 16:00-16:30

and Monday, July 13 - 11:30-12:00

SESSION 11 - FREE BASIC PRESENTATIONS

FGFR3/ FGF9 SIGNALING REGULATES A NETWORK OF PROFIBROTIC CYTOKINE AND GROWTH FACTOR PATHWAYS TO DRIVE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS IN SSC

D Chakraborty et al (DE)

A NOVEL HUMANIZED MODEL FOR SSC BY TRANSFERRING PBMC FROM PATIENTS INTO IMMUNODEFICIENT MICE

X Yu et al (DE)

FLI1-DEFICIENT ADIPOCYTES PROMOTE SPONTANEOUS SKIN FIBROSIS AND VASCULOPATHY: POTENTIAL ROLES OF ADIPOCYTES IN SSC

T Miyagawa et al (JP)

ADENO-ASSOCIATED VIRUS-5 TARGETS PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA IN LUNG AND PERIPHERAL BLOOD OF PATIENTS WITH SYSTEMIC SCLEROSIS AND ELICITS STIMULATORY ANTIBODIES

A Gabrielli et al (IT)

TGFBRII-FC REDUCES FIBROSIS AND IMPROVES LUNG FUNCTION IN FOS-RELATED ANTIGEN-2 TRANSGENIC MICE, A MODEL OF SSC

G Li et al (USA)

Discussion at live congress:

Sunday, July 12 - 16:30-17:00

and Monday, July 13 - 11:00-11:30

SESSION 12 - THE DEBATE: NEW TREATMENTS ON THE HORIZON

Nintedanib versus tocilizumab for treating SSc-ILD

O Distler (CH) and D Khanna (USA)

Discussion at live congress:

Tuesday, July 14 - 12:00-12:15 & 15:00-15:15

SESSION 13 - SPECIAL ISSUES

SIBO: screening, diagnosis and treatment by a gastroenterologist
SL Chatzinikolaou (UK)

How imaging has improved the management of scleroderma in the last 10 years

M Vonk (NL)

The role of rehabilitation and exercising in the management of the various SSc manifestations

N Mugii (JP)

Vaccination of patients with autoimmune diseases: lights and shadows

P Bonanni (IT)

Discussion at live congress:

Sunday, July 12 - 17:00-17:30

and Monday, July 13 - 09:30-10:00

SESSION 14 - SKIN

Outcomes regarding skin involvement: performance of mRSS and measurement of skin fibrosis beyond mRSS

J Pope (CA)

BIO-SAMPLES FROM AT RISK SSC PATIENTS SHOW CLASSIC PATHOLOGICAL SIGNS OF SCLERODERMA: OPPORTUNITY FOR A DIAGNOSIS OF PRE-CLINICAL SSC

R Ross et al (UK)

OPTICAL COHERENCE TOMOGRAPHY OF THE SKIN DETECTS SCLERODERMA CHANGES IN CLINICALLY UNAFFECTED SKIN: AN OPPORTUNITY FOR EARLY DETECTION OF SSC

G Abignano et al (IT)

EXPLORING ASSOCIATION BETWEEN SKIN SCORE TRAJECTORY, SURVIVAL AND PULMONARY OUTCOME IN DIFFUSE CUTANEOUS SSC

S Nihtyanova et al (UK)

Discussion at live congress:

Sunday, July 12 - 17:30-18:00

and Monday, July 13 - 10:30-11:00

SESSION 15 - AUTOIMMUNITY FORUM

Why we develop overlapping autoimmune diseases

Y Shoenfeld (IL)

Antisynthetase syndrome

L Cavagna (IT)

Autoantibodies in interstitial lung disease and autoimmune rheumatic conditions

X Bossuyt (BE)

Discussion at live congress:

Sunday, July 12 - 18:00-18:30

and Monday, July 13 - 10:00-10:30

SESSION 16 - SESSION THERAPY

Progresses in the treatment of SSC- five examples from real life

M Hinchcliff (USA)

DOES DOSE ADJUSTMENT AFFECT DECLINE IN FORCED VITAL CAPACITY IN PATIENTS TREATED WITH NINTEDANIB? DATA FROM THE SENSISC TRIAL

M Mayes et al (USA)

INTENSIFIED IMMUNOSUPPRESSION COMBINED WITH PLASMAPHERESIS HAS FAVORABLE LONG TERM EFFECTS IN PATIENTS WITH EARLY-ONSET PROGRESSIVE SSC-INTERSTITIAL LUNG DISEASE

J Potjewijd et al (NL)

RELATIONSHIP OF BASELINE MEASURES TO THE CHANGE IN THE FORCED VITAL CAPACITY IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC

D Khanna et al (USA)

SAFETY AND EFFICACY OF ABATACEPT IN EARLY DIFFUSE CUTANEOUS SSC: RESULTS FROM THE OPEN-LABEL EXTENSION OF A PHASE II INVESTIGATOR-INITIATED RANDOMIZED CONTROLLED TRIAL

L Chung et al (USA)

RISK FACTORS AND LONG-TERM FOLLOW UP OF PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS

N Blank et al (DE)

RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIB STUDY (RISE-SSC)

O Distler et al (CH)

Discussion at live congress:

Tuesday, July 14 - 12:15-12:45 & 15:45-16:15

LET'S LOOK AT

TOTALITY
in **SYSTEMIC SCLEROSIS**

Stop by our booth, or visit TotalSSc.com



LIVE CONGRESS Central European Summer Time (CEST)

During the three live congress days, the congress presentations will only be discussed in the Live Discussion Sessions with the available speakers, as indicated in the following programme. Live chat questions will be possible during live discussions.

Please indicate the name of the speaker before the question (@+name of the speaker+question).

Discussion sessions will be repeated twice along the three days, possibly with same questions.

Live E-Congress programme will run on Central European Summer Time (CEST).

The live congress days will be recorded and available in the "ON DEMAND" section **until December 20, 2020.**

SUNDAY, JULY 12

09:00-09:30	OPENING CEREMONY
09:30-10:00	Discussion Session 4 - PULMONARY
10:00-10:30	Discussion Session 5 - HEART
10:30-10:45	Discussion Session 7 - HORIZON 2020 THE BEST FROM THE DESSCIPHER PROJECT
10:45-11:15	Discussion Session 9 - VASCULAR
11:15-11:45	Discussion Session 8 - BASIC SESSION 1°
11:45-12:15	Discussion Session 6 - SPECIAL SYMPOSIUM HIGHLIGHTS IN SSC RESEARCH ACROSS JOURNALS: CONTRIBUTION FROM THE RECENT LITERATURE
13:30-14:30	MSD/BAYER SATELLITE SYMPOSIUM
14:30-15:30	CORBUS SATELLITE SYMPOSIUM
16:00-16:30	Discussion Session 10 FREE CLINICAL PRESENTATIONS
16:30-17:00	Discussion Session 11 FREE BASIC PRESENTATIONS
17:00-17:30	Discussion Session 13 - SPECIAL ISSUES
17:30-18:00	Discussion Session 14 - SKIN
18:00-18:30	Discussion Session 15 - AUTOIMMUNITY FORUM

MONDAY, JULY 13

09:30-10:00	Discussion Session 13 - SPECIAL ISSUES
10:00-10:30	Discussion Session 15 AUTOIMMUNITY FORUM
10:30-11:00	Discussion Session 14-SKIN
11:00-11:30	Discussion Session 11 FREE BASIC PRESENTATIONS
11:30-12:00	Discussion Session 10 FREE CLINICAL PRESENTATIONS
13:30-15:00	JANSSEN/ACTELION SATELLITE SYMPOSIUM
15:00-15:30	SANOFI SATELLITE SYMPOSIUM
16:00-16:30	Discussion Session 8 - BASIC SESSION 1°
16:30-17:00	Discussion Session 6 - SPECIAL SYMPOSIUM HIGHLIGHTS IN SSC RESEARCH ACROSS JOURNALS: CONTRIBUTION FROM THE RECENT LITERATURE
17:00-17:30	Discussion Session 4 - PULMONARY
17:30-18:00	Discussion Session 5 - HEART
18:00-18:15	Discussion Session 7 - HORIZON 2020 THE BEST FROM THE DESSCIPHER PROJECT

TUESDAY, JULY 14

11:00-12:00	Session SSC-COVID
12:00-12:15	Discussion Session 12 - THE DEBATE
12:15-12:45	Discussion Session 16 - SESSION THERAPY
13:30-14:00	Discussion Session of BOEHRINGER INGELHEIM SATELLITE SYMPOSIUM
14:15-14:45	CSL BEHRING SATELLITE SYMPOSIUM

15:00-15:15	Discussion Session 12 - THE DEBATE: NEW TREATMENTS ON THE HORIZON
15:15-15:45	Discussion Session 9 - VASCULAR
15:45-16:15	Discussion Session 16 - SESSION THERAPY
16:15-16:35	HIGHLIGHTS OF THE CONGRESS
16:35	CLOSURE

SUNDAY, JULY 12

09:00-09:30
OPENING CEREMONY

DISCUSSION SESSIONS - MORNING 9:30-12:15

09:30-10:00
DISCUSSION SESSION 4 - PULMONARY
Chairpersons: P Carreira (ES), F Del Galdo (UK)

How to screen and follow up SSc-ILD?

A Prasse (DE)

Speaker not available during the live discussion session

Group 3 PH, to treat or no to treat?

S Gainé (IE)

"IMAGES ARE MORE THAN PICTURES, THEY ARE DATA" - EXPLORATION OF RADIOMICS ANALYSIS FOR SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE

J Schniering (CH)

DISEASE COURSE OF PROGRESSIVE INTERSTITIAL LUNG DISEASE IN SSC: A 5-YEAR FOLLOW-UP FROM THE EUSTAR DATABASE

A Hoffmann-Vold (NO)

NEW HEMODYNAMIC DEFINITIONS OF PULMONARY HYPERTENSION: IS IT USEFUL IN SSC PATIENTS?

A Volkov (RU)

VEGF-C AND ITS RECEPTOR VEGFR-3 AS POTENTIAL SERUM BIOMARKERS FOR PULMONARY ARTERIAL HYPERTENSION IN SSC

H Didriksen (NO)

Speaker not available during the live discussion session

10:00-10:30
DISCUSSION SESSION 5 - HEART

Chairpersons: A Vacca (IT), N Damjanov (RS)

Screening for myocardial disease in SSc: which tools and when?

C Bucciarelli-Ducci (UK)

Cardiac work-up in SSc: how to distinguish primary heart involvement from ordinary cardiovascular disease

M Buch (UK)

SERUM CARDIAC BIOMARKERS AND CARDIAC MRI DIFFUSE FIBROSIS MAY PREDICT THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN SYSTEMIC SCLEROSIS PATIENTS

B Dumitru Raluca (UK)

SSC MYOCARDITIS HAS UNIQUE CLINICAL, HISTOLOGICAL AND PROGNOSTIC FEATURES: COMPARATIVE ANALYSIS BETWEEN PATIENTS WITH ENDOMYOCARDIAL BIOPSY-PROVEN MYOCARDITIS

G De Luca (IT)

PRIMARY SYSTEMIC SCLEROSIS HEART INVOLVEMENT (PSSCHI): A SYSTEMATIC LITERATURE REVIEW (SLR) AND PRELIMINARY CONSENSUS-BASED DEFINITION

C Bruni (IT)

10:30-10:45
DISCUSSION SESSION 7 - HORIZON 2020
THE BEST FROM THE DESSCIPHER PROJECT

Chairperson: L Czirjak (HU)

Introduction into the desccipher Project

U Mueller-Ladner (DE)

Speaker not available during the live discussion session

Activity Indices and individualized Immunosuppression

V Lorand (H)

Functional Disability and Digital Ulcers

V Jaeger (DE)

Myocardium & Summary

U Mueller-Ladner (DE)

Speaker not available during the live discussion session

10:45-11:15
DISCUSSION SESSION 9 - VASCULAR
Chairpersons: A Herrick (UK), Y Asano (JP)

Updated Algorithm in managing DU including combination therapy

M Matusci-Cerinic (IT)

PERFORMANCE OF AUTOMATED NAILFOLD CAPILLARY COUNTING SYSTEM (AUTOCAP) IN SSC PATIENTS

A Sulli (IT)

POTENTIAL BENEFICIAL EFFECTS FOR RESVERATROL IN SCLERODERMA VASCULOPATHY

B Kahaleh (USA)

SUNDAY, JULY 12

ILOPROST USE AND MANAGEMENT OF SSC-RELATED VASCULOPATHY IN ITALIAN TERTIARY REFERRAL CENTERS: RESULTS FROM THE PROSIT STUDY

S Negrini (IT)

11:15-11:45

DISCUSSION SESSION 8 - BASIC SESSION I^o

Chairpersons: A Gabrielli (IT), J Distler (DE)

Can tissue transcriptome be used for patients stratification?

F Del Galdo (UK)

Update on circulating Biomarkers

M. Kuwana (JP)

MACHINE-LEARNING CLASSIFICATION IN THE ABATACEPT IN SYSTEMIC SCLEROSIS TRIAL (ASSET) IDENTIFIES A SUBSET OF PATIENTS THAT IMPROVE ON THERAPY VIA MODULATION OF A CD28-RELATED PATHWAY

M Whitfield (USA)

Speaker not available during the live discussion session

LARGE-SCALE EXAMINATION OF LONGITUDINAL SKIN GENE EXPRESSION AND ITS ASSOCIATIONS WITH SKIN THICKNESS IN SSC

B Skaug (USA)

SERUM INTERFERON SCORE PREDICTS WORSE CLINICAL OUTCOME AT 12 MONTHS IN DIFFUSE SSC AS MEASURED BY GLOBAL RANKED COMPOSITE SCORE (GRCS) AND ACR COMPOSITE RESPONSE INDEX IN SSC (CRISS)

F Del Galdo (UK)

INTERFERON CHEMOKINE SCORE PREDICTS RESPONSE TO TREATMENT IN SSC RELATED INTERSTITIAL LUNG DISEASE

S Assassi (USA)

11:45-12:15

DISCUSSION SESSION 6 - SPECIAL SYMPOSIUM HIGHLIGHTS IN SSC RESEARCH ACROSS JOURNALS: CONTRIBUTION FROM THE RECENT LITERATURE

Chairpersons: M Kuwana (JP), A Clark (UK), H van Epps (NL)

Journal Scleroderma & Rel Dis

Adipose-derived mesenchymal stromal/stem cells in systemic sclerosis: Alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1

S Hoffman (USA)

Speaker not available during the live discussion session

Lancet Rheumatology

Evidence-based consensus statements for the identification and management of interstitial lung disease in systemic sclerosis

A Hoffmann-Vold (NO)

Lancet Respiratory Medicine

Nintedanib in patients with progressive fibrosing interstitial lung diseases: subgroup analyses by interstitial lung disease diagnosis in the randomised, placebo-controlled INBUILD trial

A Wells (UK)

Arthritis & Rheumatology

The best highlights from A&R in 2019

J Varga (USA)

Speaker not available during the live discussion session

13:30-15:30

SATELLITE SYMPOSIA - See programme at page 24

13:30-14:30 **MSD/BAYER SATELLITE SYMPOSIUM**

14:30-15:30 **CORBUS SATELLITE SYMPOSIUM**

DISCUSSION SESSIONS - AFTERNOON 16:00-18:30

16:00-16:30

DISCUSSION SESSION 10 - FREE CLINICAL PRESENTATIONS

Chairpersons: S Bosello (IT), M Hughes (UK)

PROVISIONAL AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) COMBINED RESPONSE INDEX IN DIFFUSE CUTANEOUS SSC (CRISS) SCORE CORRELATES WITH CHANGES <DELTA> IN PATIENT-REPORTED OUTCOMES (PRO)

R Spiera (USA)

THE EFFECT OF GENDER ON OUTCOME IN SSC: DOES ANTI-TOPOISOMERASE I AUTOANTIBODY (ATA) MATTER?

J De Vries-Bouwstra (NL)

THE PATIENT JOURNEY OF SSC-ILD IN EUROPE: AN INTEGRATED ANALYSIS OF HEALTHCARE PROFESSIONAL AND PATIENT PERSPECTIVES

A Hoffmann-Vold (NO)

THE TIMELINESS AND TYPES OF CANCER IN SSC

K Gunnarsson (SE)

THE RELATIONSHIP BETWEEN GASTROINTESTINAL SEVERITY AND SYMPTOMS AND WHOLE GUT TRANSIT IN PATIENTS WITH SSC

Z McMahan (USA)

SUNDAY, JULY 12

VALIDATION OF DISEASE ACTIVITY MEASURES IN PATIENTS WITH JSSC - RESULTS FROM THE JSSC INCEPTION COHORT

I Foeldvari (DE)

16:30-17:00

DISCUSSION SESSION 11 - FREE BASIC PRESENTATIONS

Chairpersons: M Tomcik (CZ), D Furst (USA)

FGFR3/ FGF9 SIGNALING REGULATES A NETWORK OF PROFIBROTIC CYTOKINE AND GROWTH FACTOR PATHWAYS TO DRIVE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS IN SSC

D Chakraborty (DE)

A NOVEL HUMANIZED MODEL FOR SSC BY TRANSFERRING PBMC FROM PATIENTS INTO IMMUNODEFICIENT MICE

X Yu (DE)

Speaker not available during the live discussion session

FLI1-DEFICIENT ADIPOCYTES PROMOTE SPONTANEOUS SKIN FIBROSIS AND VASCULOPATHY: POTENTIAL ROLES OF ADIPOCYTES IN SSC

T Miyagawa (JP)

Speaker not available during the live discussion session

ADENO-ASSOCIATED VIRUS-5 TARGETS PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA IN LUNG AND PERIPHERAL BLOOD OF PATIENTS WITH SYSTEMIC SCLEROSIS AND ELICITS STIMULATORY ANTIBODIES

A Gabrielli (IT)

TGFBRII-FC REDUCES FIBROSIS AND IMPROVES LUNG FUNCTION IN FOS-RELATED ANTIGEN-2 TRANSGENIC MICE, A MODEL OF SSC

G Li (USA)

Speaker not available during the live discussion session

17:00-17:30

DISCUSSION SESSION 13 - SPECIAL ISSUES

Chairpersons: T Medsger (USA), G Riemekasten (DE)

SIBO: screening, diagnosis and treatment by a gastroenterologist
SL Chatzinikolaou (UK)

How imaging has improved the management of scleroderma in the last 10 years

M Vonk (NL)

The role of rehabilitation and exercising in the management of the various SSc manifestations

N Mugii (JP)

Vaccination of patients with autoimmune diseases: lights and shadows

P Bonanni (IT)

17:30-18:00

DISCUSSION SESSION 14 - SKIN

Chairpersons: E Kucharz (PL), R Becvar (CZ)

Outcomes regarding skin involvement: performance of mRSS and measurement of skin fibrosis beyond mRSS

J Pope (CA)

BIOSAMPLES FROM AT RISK SSC PATIENTS SHOW CLASSIC PATHOLOGICAL SIGNS OF SCLERODERMA: OPPORTUNITY FOR A DIAGNOSIS OF PRE-CLINICAL SSC

R Ross (UK)

OPTICAL COHERENCE TOMOGRAPHY OF THE SKIN DETECTS SCLERODERMA CHANGES IN CLINICALLY UNAFFECTED SKIN: AN OPPORTUNITY FOR EARLY DETECTION OF SSC

G Abignano (IT)

EXPLORING ASSOCIATION BETWEEN SKIN SCORE TRAJECTORY, SURVIVAL AND PULMONARY OUTCOME IN DIFFUSE CUTANEOUS SSC

S Nihtyanova (UK)

18:00-18:30

DISCUSSION SESSION 15 - AUTOIMMUNITY FORUM

Chairpersons: H Yasuoka (JP), M Hinchcliff (USA)

Why we develop overlapping autoimmune diseases

Y Shoenfeld (IL)

Antisynthetase syndrome

L Cavagna (IT)

Autoantibodies in interstitial lung disease and autoimmune rheumatic conditions

X Bossuyt (BE)

MONDAY, JULY 13

DISCUSSION SESSIONS - MORNING 9:30-12:00

09:30-10:00

DISCUSSION SESSION 13 - SPECIAL ISSUES

Chairpersons: **N Damjanov (RS)**, **G Riemekasten (DE)**

SIBO: screening, diagnosis and treatment by a gastroenterologist
SL Chatzinikolaou (UK)

How imaging has improved the management of scleroderma in the last 10 years
M Vonk (NL)

The role of rehabilitation and exercising in the management of the various SSc manifestations
N Mugii (JP)

Vaccination of patients with autoimmune diseases: lights and shadows
P Bonanni (IT)

10:00-10:30

DISCUSSION SESSION 15 - AUTOIMMUNITY FORUM

Chairpersons: **A Balbir-Gurmann (IL)**, **H Yasuoka (JP)**

Why we develop overlapping autoimmune diseases
Y Shoenfeld (IL)

Antisynthetase syndrome
L Cavagna (IT)

Autoantibodies in interstitial lung disease and autoimmune rheumatic conditions
X Bossuyt (BE)

10:30-11:00

DISCUSSION SESSION 14 - SKIN

Chairpersons: **E Kucharz (PL)**, **R Becvar (CZ)**

Outcomes regarding skin involvement: performance of mRSS and measurement of skin fibrosis beyond mRSS
J Pope (CA)

BIOSAMPLES FROM AT RISK SSC PATIENTS SHOW CLASSIC PATHOLOGICAL SIGNS OF SCLERODERMA: OPPORTUNITY FOR A DIAGNOSIS OF PRE-CLINICAL SSC
R Ross (UK)

OPTICAL COHERENCE TOMOGRAPHY OF THE SKIN DETECTS SCLERODERMA CHANGES IN CLINICALLY UNAFFECTED SKIN: AN OPPORTUNITY FOR EARLY DETECTION OF SSC
G Abignano (IT)

EXPLORING ASSOCIATION BETWEEN SKIN SCORE TRAJECTORY, SURVIVAL AND PULMONARY OUTCOME IN DIFFUSE CUTANEOUS SSC
S Nihtyanova (UK)

11:00-11:30

DISCUSSION SESSION 11 - FREE BASIC PRESENTATIONS

Chairpersons: **ME Truchetet (F)**, **M Tomcik (CZ)**

FGFR3/ FGF9 SIGNALING REGULATES A NETWORK OF PROFIBROTIC CYTOKINE AND GROWTH FACTOR PATHWAYS TO DRIVE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS IN SSC
D Chakraborty (DE)

A NOVEL HUMANIZED MODEL FOR SSC BY TRANSFERRING PBMC FROM PATIENTS INTO IMMUNODEFICIENT MICE
X Yu (DE)
Speaker not available during the live discussion session

FLI1-DEFICIENT ADIPOCYTES PROMOTE SPONTANEOUS SKIN FIBROSIS AND VASCULOPATHY: POTENTIAL ROLES OF ADIPOCYTES IN SSC
T Miyagawa (JP)
Speaker not available during the live discussion session

ADENO-ASSOCIATED VIRUS-5 TARGETS PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA IN LUNG AND PERIPHERAL BLOOD OF PATIENTS WITH SYSTEMIC SCLEROSIS AND ELICITS STIMULATORY ANTIBODIES
A Gabrielli (IT)

TGFBR1I-FC REDUCES FIBROSIS AND IMPROVES LUNG FUNCTION IN FOS-RELATED ANTIGEN-2 TRANSGENIC MICE, A MODEL OF SSC
G Li (USA)
Speaker not available during the live discussion session

MONDAY, JULY 13

11:30-12:00

DISCUSSION SESSION 10 - FREE CLINICAL PRESENTATIONS

Chairpersons: S Bosello (IT), M Hughes (UK)

PROVISIONAL AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) COMBINED RESPONSE INDEX IN DIFFUSE CUTANEOUS SSC (CRISS) SCORE CORRELATES WITH CHANGES <DELTA> IN PATIENT-REPORTED OUTCOMES (PRO)

R Spiera (USA)

THE EFFECT OF GENDER ON OUTCOME IN SSC: DOES ANTI-TOPOISOMERASE I AUTOANTIBODY (ATA) MATTER?

J De Vries-Bouwstra (NL)

THE PATIENT JOURNEY OF SSC-ILD IN EUROPE: AN INTEGRATED ANALYSIS OF HEALTHCARE PROFESSIONAL AND PATIENT PERSPECTIVES

A Hoffmann-Vold (NO)

THE TIMELINESS AND TYPES OF CANCER IN SSC

K Gunnarsson (SE)

THE RELATIONSHIP BETWEEN GASTROINTESTINAL SEVERITY AND SYMPTOMS AND WHOLE GUT TRANSIT IN PATIENTS WITH SSC

Z McMahan (USA)

VALIDATION OF DISEASE ACTIVITY MEASURES IN PATIENTS WITH JSSC - RESULTS FROM THE JSSC INCEPTION COHORT

I Foeldvari (DE)

13:30-15:30

SATELLITE SYMPOSIA - See programme at page 25

13:30-15:00 JANSSEN/ACTELION SATELLITE SYMPOSIUM

15:00-15:30 SANOFI SATELLITE SYMPOSIUM

DISCUSSION SESSIONS - AFTERNOON 16:00-18:15

16:00-16:30

DISCUSSION SESSION 8 - BASIC SESSION I^o

Chairpersons: A Gabrielli (IT), J Distler (DE)

Can tissue transcriptome be used for patients stratification?

F Del Galdo (UK)

Update on circulating Biomarkers

M. Kuwana (JP)

MACHINE-LEARNING CLASSIFICATION IN THE ABATACEPT IN SYSTEMIC SCLEROSIS TRIAL (ASSET) IDENTIFIES A SUBSET OF PATIENTS THAT IMPROVE ON THERAPY VIA MODULATION OF A CD28-RELATED PATHWAY

M Whitfield (USA)

LARGE-SCALE EXAMINATION OF LONGITUDINAL SKIN GENE EXPRESSION AND ITS ASSOCIATIONS WITH SKIN THICKNESS IN SSC

B Skaug (USA)

SERUM INTERFERON SCORE PREDICTS WORSE CLINICAL OUTCOME AT 12 MONTHS IN DIFFUSE SSC AS MEASURED BY GLOBAL RANKED COMPOSITE SCORE (GRCS) AND ACR COMPOSITE RESPONSE INDEX IN SSC (CRISS)

F Del Galdo (UK)

INTERFERON CHEMOKINE SCORE PREDICTS RESPONSE TO TREATMENT IN SSC RELATED INTERSTITIAL LUNG DISEASE

S Assassi (USA)

16:30-17:00

DISCUSSION SESSION 6 - SPECIAL SYMPOSIUM HIGHLIGHTS IN SSC RESEARCH ACROSS JOURNALS: CONTRIBUTION FROM THE RECENT LITERATURE

Chairpersons: M Kuwana (JP), A Clark (UK), H van Epps (NL)

Journal Scleroderma & Rel Dis

Adipose-derived mesenchymal stromal/stem cells in systemic sclerosis: Alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1

S Hoffman (USA)

Lancet Rheumatology

Evidence-based consensus statements for the identification and management of interstitial lung disease in systemic sclerosis

A Hoffmann-Vold (NO)

Lancet Respiratory Medicine

Nintedanib in patients with progressive fibrosing interstitial lung diseases: subgroup analyses by interstitial lung disease diagnosis in the randomised, placebo-controlled INBUILD trial

A Wells (UK)

Arthritis & Rheumatology

The best highlights from A&R in 2019

J Varga (USA)

Speaker not available during the live discussion session

MONDAY, JULY 13

17:00-17:30

DISCUSSION SESSION 4 - PULMONARY

Chairpersons: R Silver (USA), D Furst (USA)

How to screen and follow up SSc-ILD?

A Prasse (DE)

Speaker not available during the live discussion session

Group 3 PH, to treat or no to treat?

S Gainé (IE)

"IMAGES ARE MORE THAN PICTURES, THEY ARE DATA" - EXPLORATION OF RADIOMICS ANALYSIS FOR SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE

J Schniering (CH)

DISEASE COURSE OF PROGRESSIVE INTERSTITIAL LUNG DISEASE IN SSC: A 5-YEAR FOLLOW-UP FROM THE EUSTAR DATABASE

A Hoffmann-Vold (NO)

NEW HEMODYNAMIC DEFINITIONS OF PULMONARY HYPERTENSION: IS IT USEFUL IN SSC PATIENTS?

A Volkov (RU)

VEGF-C AND ITS RECEPTOR VEGFR-3 AS POTENTIAL SERUM BIOMARKERS FOR PULMONARY ARTERIAL HYPERTENSION IN SSC

H Didriksen (NO)

Speaker not available during the live discussion session

17:30-18:00

DISCUSSION SESSION 5 - HEART

Chairpersons: A Vacca (IT), T Medsger (USA)

Screening for myocardial disease in SSc: which tools and when?

C Bucciarelli-Ducci (UK)

Cardiac work-up in SSc: how to distinguish primary heart involvement from ordinary cardiovascular disease

M Buch (UK)

SERUM CARDIAC BIOMARKERS AND CARDIAC MRI DIFFUSE FIBROSIS MAY PREDICT THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN SYSTEMIC SCLEROSIS PATIENTS

B Dumitru Raluca (UK)

SSC MYOCARDITIS HAS UNIQUE CLINICAL, HISTOLOGICAL AND PROGNOSTIC FEATURES: COMPARATIVE ANALYSIS BETWEEN PATIENTS WITH ENDOMYOCARDIAL BIOPSY-PROVEN MYOCARDITIS

G De Luca (IT)

PRIMARY SYSTEMIC SCLEROSIS HEART INVOLVEMENT (PSSCHI): A SYSTEMATIC LITERATURE REVIEW (SLR) AND PRELIMINARY CONSENSUS-BASED DEFINITION

C Bruni (IT)

18:00-18:15

DISCUSSION SESSION 7 - HORIZON 2020

THE BEST FROM THE DESSCIPHER PROJECT

Chairperson: L Czirjak (HU)

Introduction into the desscipher Project

U Mueller-Ladner (DE)

Speaker not available during the live discussion session

Activity Indices and individualized Immunosuppression

V Lorand (H)

Functional Disability and Digital Ulcers

V Jaeger (DE)

Myocardium & Summary

U Mueller-Ladner (DE)

Speaker not available during the live discussion session

TUESDAY, JULY 14

11:00-12:00

SESSION SSC-COVID

Chairpersons: AM Iagnocco (IT), M Matucci-Cerinic (IT)

Introduction

M Matucci-Cerinic (IT)

Physiopathology of COVID, similarities with SSc

C Campochiaro (IT)

SSc-COVID: the voice of the literature

C Bruni (IT)

Scleroderma in the centre of a COVID storm

C Denton (UK)

EUSTAR registry for COVID-SSc cases

O Distler (CH)

EULAR activities in the COVID era

AM Iagnocco (IT)

Discussion

DISCUSSION SESSIONS - MORNING 12:00-12:45

12:00-12:15

DISCUSSION SESSION 12. THE DEBATE: NEW TREATMENTS ON THE HORIZON

Chairpersons: M Baron (CA), V Steen (USA)

Nintedanib versus tocilizumab for treating SSc-ILD

O Distler (CH) and D Khanna (USA)

12:15-12:45

DISCUSSION SESSION 16 - SESSION THERAPY

Chairpersons: D Khanna (USA), J Van Laar (NL)

Progresses in the treatment of SSc- five examples from real life

M Hinchcliff (USA)

Speaker not available during the live discussion session

DOES DOSE ADJUSTMENT AFFECT DECLINE IN FORCED VITAL CAPACITY IN PATIENTS TREATED WITH NINTEDANIB? DATA FROM THE SENSIC TRIAL

M Mayes (USA)

INTENSIFIED IMMUNOSUPPRESSION COMBINED WITH PLASMAPHERESIS HAS FAVORABLE LONG TERM EFFECTS IN PATIENTS WITH EARLY-ONSET PROGRESSIVE SSC-INTERSTITIAL LUNG DISEASE

J Potjewijd (NL)

RELATIONSHIP OF BASELINE MEASURES TO THE CHANGE IN THE FORCED VITAL CAPACITY IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC

D Khanna (USA)

SAFETY AND EFFICACY OF ABATACEPT IN EARLY DIFFUSE CUTANEOUS SSC: RESULTS FROM THE OPEN-LABEL EXTENSION OF A PHASE II INVESTIGATOR-INITIATED RANDOMIZED CONTROLLED TRIAL

L Chung (USA)

Speaker not available during the live discussion session

RISK FACTORS AND LONG-TERM FOLLOW UP OF PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS

N Blank (DE)

RIOCIQUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIB STUDY (RISE-SSC)

O Distler (CH)

13:30-14:45

SATELLITE SYMPOSIA - See programme at page 26

**13:30-14:00 Discussion session of
BOEHRINGER INGELHEIM
SATELLITE SYMPOSIUM**

14:15-14:45 CSL BEHRING SATELLITE SYMPOSIUM

DISCUSSION SESSIONS - AFTERNOON 15:00-16:15

15:00-15:15

DISCUSSION SESSION 12. THE DEBATE: NEW TREATMENTS ON THE HORIZON

Chairpersons: M Baron (CA), V Steen (USA)

Nintedanib versus tocilizumab for treating SSc-ILD

O Distler (CH) and D Khanna (USA)

TUESDAY, JULY 14

15:15-15:45

DISCUSSION SESSION 9 - VASCULAR

Chairpersons: T Frech (USA), A Herrick (UK)

Updated Algorithm in managing DU including combination therapy
M Matucci-Cerinic (IT)

PERFORMANCE OF AUTOMATED NAILFOLD CAPILLARY COUNTING SYSTEM (AUTOCAPI) IN SSC PATIENTS

A Sulli (IT)

POTENTIAL BENEFICIAL EFFECTS FOR RESVERATROL IN SCLERODERMA VASCULOPATHY

B Kahaleh (USA)

ILOPROST USE AND MANAGEMENT OF SSC -RELATED VASCULOPATHY IN ITALIAN TERTIARY REFERRAL CENTERS: RESULTS FROM THE PROSIT STUDY

S Negrini (IT)

15:45-16:15

DISCUSSION SESSION 16 - SESSION THERAPY

Chairpersons: L Chung (USA), V Nagaraja (USA)

Progresses in the treatment of SSc- five examples from real life

M Hinchcliff (USA)

Speaker not available during the live discussion session

DOES DOSE ADJUSTMENT AFFECT DECLINE IN FORCED VITAL CAPACITY IN PATIENTS TREATED WITH NINTEDANIB? DATA FROM THE SENSISCIS TRIAL

M Mayes (USA)

INTENSIFIED IMMUNOSUPPRESSION COMBINED WITH PLASMAPHERESIS HAS FAVORABLE LONG TERM EFFECTS IN PATIENTS WITH EARLY-ONSET PROGRESSIVE SSC-INTERSTITIAL LUNG DISEASE

J Potjewijd (NL)

RELATIONSHIP OF BASELINE MEASURES TO THE CHANGE IN THE FORCED VITAL CAPACITY IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC

D Khanna (USA)

SAFETY AND EFFICACY OF ABATACEPT IN EARLY DIFFUSE CUTANEOUS SSC: RESULTS FROM THE OPEN-LABEL EXTENSION OF A PHASE II INVESTIGATOR-INITIATED RANDOMIZED CONTROLLED TRIAL

L Chung (USA)

RISK FACTORS AND LONG-TERM FOLLOW UP OF PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS
N Blank (DE)

RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIB STUDY (RISE-SSC)

O Distler (CH)

16:15-16:35

HIGHLIGHTS OF THE CONGRESS

Y Allanore (FR)

16:35

CLOSURE OF THE CONGRESS

LIVE SATELLITE SYMPOSIA

SUNDAY, JULY 12

13:30-14:30	MSD/BAYER SATELLITE SYMPOSIUM
14:30-15:30	CORBUS SATELLITE SYMPOSIUM

MONDAY, JULY 13

13:30-15:00	JANSSEN/ACTELION SATELLITE SYMPOSIUM
15:00-15:30	SANOFI SATELLITE SYMPOSIUM

TUESDAY, JULY 14

13:30-14:00	Discussion Session of BOEHRINGER INGELHEIM DISCUSSION SATELLITE SYMPOSIUM <i>Presentations will be recorded only and available in the "RECORDED PRESENTATIONS" and "ON DEMAND" sections from Monday, July 13</i>
14:15-14:45	CSL BEHRING SATELLITE SYMPOSIUM

SUNDAY, JULY 12

MSD/BAYER SATELLITE SYMPOSIUM

13:30-14:30

**UPDATES ON CONNECTIVE TISSUE DISEASE ASSOCIATED
PULMONARY ARTERIAL HYPERTENSION**

Chairperson: M Matucci-Cerinic (IT)

13:30-13:45

Systemic sclerosis: Cardio pulmonary manifestation

D Khanna (USA)

13:45-14:00

PAH in systemic sclerosis: how to optimize detection

AM Hoffmann-Vold (NO)

14:00-14:15

Potential role of sGC stimulation in PAH-CTD patients

E Grünig (DE)

14:15-14:25

Round Table Q&A

M Matucci-Cerinic (IT)

14:25-14:30

Summary and Close

M Matucci-Cerinic (IT)

CORBUS PHARMACEUTICALS SATELLITE SYMPOSIUM

14:30-15:30

**THE ROLE OF THE ENDOCANNABINOID SYSTEM (ECS) IN
CHRONIC INFLAMMATION AND FIBROSIS**

Chairpersons: C Denton (UK), T Frech (USA)

Biology of the ECS with a focus on inflammation and fibrosis

C Denton (UK)

Targeting systemic sclerosis and other inflammatory/fibrotic
diseases with CB2 agonism

T Frech (USA)

Lenabasum clinical development update

T Frech (USA)

MONDAY, JULY 13

JANSSEN/ACTELION SATELLITE SYMPOSIUM

13:30-15:00

**EARLY DIAGNOSIS AND TREATMENT INITIATION: MODERN
PATIENT MANAGEMENT IN SSC-PAH**

Chairpersons: P Jansa (CZ), M Matucci-Cerinic (IT)

13:30-13:40

Welcome and introduction

P Jansa (CZ)

13:40-13:52

Screening for PAH in patients with SSc

D Khanna (USA)

13:52-14:04

Early and correct diagnosis of PAH is key in patients with SSc

E Hachulla (FR)

14:04-14:16

Assessing risk to make timely treatment decisions

S Gaine (IE)

14:16-14:30

Treatment strategies in SSc-PAH: Clinical evidence and the patient perspective

J Pope (USA)

14:30-14:50

Panel discussion and audience questions

All

14:50-15:00

Key messages and closing remarks

M Matucci-Cerinic (IT)

SANOFI SATELLITE SYMPOSIUM

15:00-15:30

**TH2 INFLAMMATION AND FIBROSIS IN SYSTEMIC
SCLEROSIS**

15:00-15:20

A Subramaniam (USA)

15.20-15:30

Discussion

TUESDAY, JULY 14

BOEHRINGER INGELHEIM DISCUSSION SATELLITE SYMPOSIUM

13:30-14:00

LIVE QUESTIONS AND ANSWERS

Pre-recorded presentations available from Monday, July 13 in the "RECORDED PRESENTATIONS" and "ON DEMAND" sections.

NEW PARADIGMS IN THE MANAGEMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD)

Chairperson: O Distler (CH)

Welcome and introduction (pre-recorded) - 10 mins

O Distler (CH)

Natural course of SSc-ILD: what do we know? (pre-recorded) - 20 mins

M Vonk (NL)

Treatment of SSc-ILD: whom and when? (pre-recorded) - 20 mins

D Khanna (USA)

Questions and answers (live)

All

CSL BEHRING SATELLITE SYMPOSIUM

14:15-14:45

EMERGING TREATMENT / MECHANISM OF SSc

14:15-14:25

Emerging therapies in SSc

D Khanna (USA)

14:25-14:35

Intravenous immunoglobulin in SSc

M Matucci-Cerinic (IT)

14:35-14:45

Discussion

POSTER SESSION

Posters will be charged into the platform at disposal for all participant.
Authors will have at disposal a 3-minutes recording speech to be integrated to the poster file.

PATHOGENESIS (AUTOANTIBODIES)

- P.001** **REGULATOR COMBINATIONS IDENTIFY SYSTEMIC SCLEROSIS PATIENTS WITH MORE SEVERE DISEASE**
[Y. Wang](#), [J. Franks](#), [D. Toledo](#), [M. Whitfield](#)
- P.002** **EPIGENETIC INSIGHTS FROM DIFFERENTIAL CHROMATIN ACCESSIBILITY PATTERNS IN DERMAL FIBROBLASTS AND SKIN-LIKE ORGANOID FROM PATIENTS WITH SYSTEMIC SCLEROSIS**
[T. Wheeler](#), [Y. Wang](#), [J. Chang](#), [D.M. Toledo](#), [B.K. Mehta](#), [M.S. Brown](#), [R. Bhandari](#), [M. Huang](#), [T. Wood](#), [P.A. Pioli](#), [M.L. Whitfield](#)
- P.003** **EXOME-WIDE ASSOCIATION ANALYSIS IDENTIFIES LRP2BP AS A SUSCEPTIBILITY GENE FOR ENDOTHELIAL INJURY IN SYSTEMIC SCLEROSIS**
[J. Wang](#), [W. Pu](#), [W. Wu](#), [Q. Liu](#), [Y. Ma](#), [W. Tu](#), [X. Zuo](#), [G. Guo](#), [S. Jiang](#), [Y. Zhao](#), [J. Reveille](#), [M. Mayes](#), [J. Li](#), [E. Lee](#), [X. Zhang](#), [J. Xu](#), [Z. Zhang](#), [X. Zhou](#), [H. Zou](#)
- P.004** **INCREASED PLATELET DEPOSITION UNDER SHEAR STRESS CONDITIONS IN PATIENTS WITH SCLERODERMA**
[I. Vigdorick](#), [Y. Levy](#)
- P.005** **ANTICENTROMERE ANTIBODY LEVELS AND ISOTYPES ASSOCIATE WITH DISEASE SEVERITY IN SYSTEMIC SCLEROSIS**
[N. Van Leeuwen](#), [J. Bakker](#), [O. Distler](#), [A. Hoffman-Vold](#), [A. Grummels](#), [C. Wortel](#), [H. Fretheim](#), [S. Jordan](#), [T. Huizinga](#), [R. Toes](#), [H. Scherer](#), [J. De Vries-Bouwstra](#)
- P.006** **SPECIFIC IMMUNODOMINANT PDGF α AND NADPH OXIDASE HLA-I TRANS-SPICED PEPTIDES ARE DEMONSTRATED IN SSC LYMPHOCYTES**
[S. Svegliati](#), [G. Moroncini](#), [T. Spadoni](#), [M. Mozzicafreddo](#), [M. Cuccioloni](#), [A. Grieco](#), [C. Paolini](#), [C. Tonnini](#), [S. Agarbati](#), [A. Funaro](#), [A. Gabrielli](#), [E. Avvedimento](#)
- P.007** **PATHOGENIC ACTIVATION OF MESENCHYMAL STEM CELLS IS INDUCED BY THE DISEASE MICROENVIRONMENT IN SYSTEMIC SCLEROSIS**
[Y. Suleman](#), [H. Liu](#), [Z. Taki](#), [E. Gostjeva](#), [W. Thilly](#), [H. Lopez](#), [S. Vigneswaran](#), [B. Ahmed Abdi](#), [C. Denton](#), [S. O Reilly](#), [S. Xu](#), [R. Stratton](#)
- P.008** **ALPHA- SMOOTH MUSCLE ACTIN EXPRESSION ON ENDOTHELIAL PROGENITORS CELLS OF SYSTEMIC SCLEROSIS (SSC) PATIENTS: POSSIBLE ROLE IN THE ENDOTHELIAL-TO-MESENCHYMAL TRANSITION PROCESS**
[K. Stefanantoni](#), [C. Barbati](#), [T. Colasanti](#), [C. Angelelli](#), [G. Pellegrino](#), [C. Alessandri](#), [G. Valesini](#), [V. Riccieri](#)
- P.009** **CLINICAL SIGNIFICANCE OF ISOLATED R052/TRIM21 AUTOANTIBODIES IN THE WAIKATO HOSPITAL SYSTEMIC SCLEROSIS COHORT**
[K. Solanki](#), [P. Bardoul](#), [A. Soepnoel](#), [D. White](#), [M. Matucci-Cerinic](#)
- P.010** **IS ANTI-DOUBLE-STRANDED, SINGLE-STRANDED DNA ANTI-C1Q ANTIBODY SEROPOSITIVITY A DISEASE MARKER IN PATIENTS WITH SYSTEMIC SCLEROSIS?**
[T. Simopoulou](#), [E. Patrikiou](#), [C. Liaskos](#), [G. Efthymiou](#), [L. Sakkas](#), [D. Bogdanos](#)
- P.011** **CD34 AND ALPHA-SMOOTH MUSCLE ACTIN DISTINGUISH SCLERODERMA GENE EXPRESSION SUBSETS USING A MACHINE LEARNING APPROACH**
[K. Showalter](#), [D. Orange](#), [C. Magro](#), [P. Agius](#), [V. Martyanov](#), [J. Franks](#), [R. Sharma](#), [H. Geiger](#), [T. Wood](#), [Y. Zhang](#), [R. Spiera](#), [M. Whitfield](#), [J. Gordon](#)
- P.012** **OCCURRENCE OF DIFFERENT ANTINUCLEAR ANTIBODIES IN PATIENTS WITH SYSTEMIC SCLEROSIS POSITIVE FOR ANTI-U1RNP**
[R. Shvakhmetova](#), [L. Ananieva](#), [O. Koneva](#), [M. Starovoitova](#), [O. Desinova](#), [O. Ovsyannikova](#), [L. Garzanova](#)
- P.013** **NOTCH SIGNALING IN MICROVASCULAR ENDOTHELIAL CELLS IS MODULATED BY A SERUM FACTOR IN SYSTEMIC SCLEROSIS**
[F. Seguro Paula](#), [J. Delgado Alves](#)
- P.014** **SPECIFIC AUTOANTIBODIES IN SYSTEMIC SCLEROSIS AND ITS CORRELATION WITH CLINICAL MANIFESTATION IN WEST JAVA INDONESIA**
[W. Saragih](#), [S. Dewi](#), [R. Wachjudi](#), [V. Logito](#), [A. Tjandrawati](#)
- P.015** **DISSECTING THE ROLE OF IL-25 IN KERATINOCYTE-FIBROBLAST CROSSTALK IN SYSTEMIC SCLEROSIS**
[B. Russo](#), [J. Borowczyk-Michalowska](#), [P. Cacialli](#), [N. Brembilla](#), [C. Chizzolini](#)
- P.016** **CD25+ FOXP3+ REGULATORY B CELLS FUNCTION IN SYSTEMIC SCLEROSIS**
[D. Rimar](#), [G. Slobodin](#), [I. Rosner](#), [M. Rozenbaum](#), [E. Nasrin](#), [Z. Vadasz](#)
- P.017** **IS IGG4 AN IMMUNO-PROTECTIVE ANTIBODY? LESSONS FROM SYSTEMIC SCLEROSIS**
[N. Rabinowicz](#), [A. Ben Ari](#), [H. Paran](#), [Y. Levy](#)
- P.018** **EVALUATION OF MEMBRANE-BOUND AND SOLUBLE FORMS OF HUMAN LEUCOCYTE ANTIGEN G (HLA-G) IN SYSTEMIC SCLEROSIS**
[P. Contini](#), [S. Negrini](#), [G. Murdaca](#), [M. Greco](#), [F. Puppo](#)
- P.019** **ANTI-IFI-16 AUTOANTIBODIES IN SYSTEMIC SCLEROSIS PATIENTS ARE ASSOCIATED WITH A POORER PROGNOSIS IN OVERALL SURVIVAL**
[J. Perurena-Prieto](#), [E.L. Callejas-Moraga](#), [A. Guillén-Del-Castillo](#), [L. Viñas-Gimenez](#), [A. Marín-Sánchez](#), [V. Fonollosa-Plá](#), [M.T. Sanz-Martínez](#), [C. P. Simeón-Aznar](#)

PATHOGENESIS (AUTOANTIBODIES)

- P.020** **INKT CELLS MODULATE REGULATORY AND EFFECTOR B CELLS OF SSC PATIENTS**
E. Asteriti, H. Keppeler, S. Duerr-Stoerzer, H. Schmid, K. Secker, A. Pecher, J. Henes, R. Klein, C. Schneidawind, D. Schneidawind
- P.021** **DEFECTIVE DNA DAMAGE RESPONSE AND REPAIR NETWORK IN PATIENTS WITH SYSTEMIC SCLEROSIS**
M. Pappa, P. Ntouros, N. Vlachogiannis, S. Panopoulos, V. Bournia, V. Souliotis, P. Sfrikakis
- P.022** **SKIN SINGLE-CELL RNA SEQUENCING AND TARGET VALIDATION IN SYSTEMIC SCLEROSIS AND SCLEROTIC GVHD**
I. Odell, R. Flavell
- P.023** **CLINICAL CHARACTERISTICS OF SYSTEMIC SCLEROSIS (SSC) PATIENTS NEGATIVE FOR SSC-RELATED AUTOANTIBODIES**
M. Miyake, Y. Hamaguchi, T. Matsushita, K. Takehara
- P.024** **ROLE OF EFFECTOR AND REGULATORY B CELLS IN PATIENTS WITH SYSTEMIC SCLEROSIS: IL-6 PRODUCING EFFECTOR B CELLS ASSOCIATED WITH SKIN FIBROSIS**
T. Matsushita, T. Kobayashi, M. Kano, Y. Hamaguchi, M. Hasegawa, M. Fujimoto, K. Takehara
- P.025** **CORRELATIONS BETWEEN NEUTROPHILS/LYMPHOCYTES RATIO AND PLATELETS/LYMPHOCYTES RATIO IN CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS**
F. Masini, F. Guarino, K. Gjeloshi, F. Danzo, E. Pinotti, R. Ferrara, M. Tardugno, L. Maresca, C. Romano, G. Cuomo
- P.026** **THE INTERCONNECTIONS BETWEEN ACTIVITIES OF THE OXIDATIVE-RELATED ENZYMES AND DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS**
E. Mozgovaya, S. Bedina, A. Trofimenko, I. Zborovskaya, M. Mamus, E. Tikhomirova, S. Spitsina
- P.027** **WITHDRAWN**
- P.028** **CORRELATION OF ANTINUCLEAR AUTOANTIBODIES, SOLUBLE TGF- β ISOFORMS, AND TGFB1 +869T>C AND +915G>C POLYMORPHISMS IN PATIENTS OF SOUTHERN MEXICO WITH SYSTEMIC SCLEROSIS**
J. Lomeli Nieto, J. Muñoz Valle, C. Baños Hernández, J. Navarro Zarza, S. García Arellano, B. Anaya Macias, C. Fuentes Baez, I. Parra Rojas, J. Hernández Bello
- P.029** **THE LABORATORY STRATEGY FOR ANTIBODIES SCREENING AND SPECIFIC ANTIGEN DETECTION AS DIAGNOSTIC MARKER OF PULMONARY FIBROSIS IN SYSTEMIC SCLEROSIS: PRELIMINARY STUDY**
V. Logito, W. Agnestia Maranna Saragih, A. Tjandrawati, S. Dewi
- P.030** **CRYSTALLINE SILICA IMPAIRS EFFEROCYTOSIS ABILITIES OF HUMAN AND MOUSE MACROPHAGES**
A. Lescoat, A. Ballerie, M. Lelong, Y. Augagneur, C. Morzadec, S. Jouneau, P. Jegou, O. Fardel, L. Vernhet, V. Lecureur
- P.031** **AN ITALIAN MULTICENTER STUDY ON THE ASSOCIATION OF ANTI-RNA POLYMERASE III ANTIBODY WITH BREAST CANCER AND SILICONE BREAST IMPLANTS RUPTURE IN PATIENTS WITH SYSTEMIC SCLEROSIS**
M. Lazzaroni, C. Caimmi, E. Bertoldo, C. Campochiaro, G. De Luca, F. Franceschini, A. Tincani, P. Airò
- P.032** **ANTI-PM/SCL ANTIBODY IN PATIENTS WITH SYSTEMIC SCLEROSIS. ANALYSIS OF THE MULTICENTER EUSTAR COHORT, WITH A CASE-CONTROL STUDY ON ASSOCIATION WITH MALIGNANCIES**
M. Lazzaroni, E. Marasco, C. Campochiaro, J. Devries-Bouwstra, E. Hachulla, E. Zanatta, S. Barsotti, G. Abignano, M. Truchetet, G. De Luca, E. De Langhe, R. Hesselstrand, F. Ingegnoli, E. Bertoldo, C. Caimmi, V. Smith, S. Bellando-Randone, H. Poormoghim, E. Colombo, A. Ceribelli, A. Furloni, S. Zingarelli, F. Franceschini, F. Del Galdo, C. Denton, L. Cavagna, Y. Allanore, P. Airò
- P.033** **DISCOVERY OF T CELL EPITOPES FROM THE AUTOANTIGENS IMPLICATED IN SYSTEMIC SCLEROSIS: AN IN SILICO APPROACH**
M. Larche, B. Duvvuri, R. Quinn, M. Larche
- P.034** **THE ROLE OF DIFFERENT ANTINUCLEAR ANTIBODIES IN VASCULAR LESIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS**
N. Klyaus, M. Simakova, A. Maslyanskiy, O. Moiseeva
- P.035** **MALE MICROCHIMERISM IN SSC PATIENTS**
J. Milas Ahic, Z. Kardum, S. Tokic, V. Prus
- P.036** **EPIDEMIOLOGY AND TREATMENT OF PERIPHERAL NEUROPATHY IN SYSTEMIC SCLEROSIS**
B. Almejradi, F. To, K. Devakandan, M. Anderson, S. Johnson
- P.037** **AUTOANTIBODIES TARGETING CXCR3, CXCR4 AND AT1R AFFECT THE EXPRESSION OF THEIR COGNATE RECEPTORS IN THE APOE KO MOUSE MODEL**
L. Johanson, L. Brachaczek, Z. Aherrahou, G. Marschner, S. Pitann, A. Kerstein-Stähle, A. Müller, H. Heidecke, C. Herden, G. Riemekasten
- P.038** **A PILOT STUDY ASSESSING THE EFFECT OF AIR POLLUTION ON EXTRACELLULAR VESICLES IN SYSTEMIC SCLEROSIS**
F. Ingegnoli, T. Schioppo, M. Hoxha, S. Iodice, L. Pergoli, A. Murgio, L. Ferrari, V. Bollati, R. Caporali
- P.039** **SYSTEMIC SCLEROSIS WITHOUT ANTINUCLEAR ANTIBODIES: A MULTI-CENTER STUDY OF EUSTAR COHORT IN CHINA**
M. Hui, J. Zhou, X. Duan, L. Zhang, M. Li, Q. Wang, J. Zhao, Y. Hou, D. Xu, X. Zeng
- P.040** **CD21LOW B CELLS IN SYSTEMIC SCLEROSIS: A POSSIBLE MARKER OF PULMONARY ARTERIAL HYPERTENSION**
C. Pellicano, R. Marrapodi, G. Leodori, G. Radicchio, S. Colantuono, A. Iacolare, A. Gigante, M. Visentini, E. Rosato
- P.041** **TOXIC EXPOSURE SURVEY IN A SYSTEMIC SCLEROSIS COHORT**
M. Freire, B. Sopena, A. Gonzalez-Quintela, C. Tolosa Vilella, A. Guillén Del Castillo, B. Mari Alfonso, J. Vargas Hitos, X. Pla Salas, C. González-Echavarrí, A. Chamorro, I. Perales Fraile, A. González García, G. de la Red Bellvis, D. Bernal Bello, A. Castro Salomó, I. Jiménez Pérez de Heredia, E. Callejas Moraga, V. Fonollosa Pla, C. Simeon Aznar, On behalf of RESCLE Investigators
- P.042** **IMPROVING CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS, A EUSTAR STUDY**
M. Elhai, M. Boubaya, E. Siegert, V. Riccieri, P. Airò, O. Distler, Y. Allanore
- P.043** **SYSTEMIC SCLERODERMA: CLINICO-IMMUNOLOGICAL CORRELATION**
K. Echchilali, K. Ouazhrouh, H. Elkabli, A. Aziz Bousfifa

PATHOGENESIS (AUTOANTIBODIES)

- P.044** LONG NON-CODING RNA HOTAIR INDUCES MYOFIBROBLAST ACTIVATION IN SYSTEMIC SCLEROSIS THROUGH EZH2 DEPENDENT DE-REPRESSION OF NOTCH SIGNALLING PATHWAY ACTIVATION
F. Del Galdo, C. Wasson, G. Abignano, R. Ross, H. Hermes, S. Jimenez
- P.045** TGF β 2 PROMOTES DNA METHYLATION OF THE SOCS3 PROMOTER TO INDUCE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS IN SSC
C. Dees, S. Pötter, Y. Zhang, C. Bergmann, M. Luber, T. Wohlfahrt, A. Ramming, O. Distler, G. Schett, J. Distler
- P.046** IL-1 BETA-STIMULATED MICROVASCULAR ENDOTHELIAL CELLS PROMOTE M2-LIKE MACROPHAGES: CONSEQUENCES ON FIBROBLASTS ACTIVATION DURING SCLERODERMA
C. Contin-Bordes, P. Laurent, J. Lapoirie, B. Jurado-Mestre, E. Leviaonnois, M. Truchetet
- P.047** EXOSOMES IN SYSTEMIC SCLEROSIS (SSC): HOW TO SPREAD THE PRO-FIBROTIC SIGNALLING IN THE DISEASE
C. Corallo, M. Cutolo, S. Soldano, N. Giordano
- P.048** SERUM MARKER ANALYSIS SUGGESTS SUBSET AND STAGE SPECIFIC PROFILES OF FIBROGENESIS ACROSS THE SCLERODERMA SPECTRUM
K.E.N. Clark, C. Campochiaro, K. Nevin, E. Csomor, N. Galwey, M. Morse, N. Wisniacki, S. Flint, V.H. Ong, E. Derrett-Smith, C.P. Denton
- P.049** ANTIBODIES VERSUS SKIN FIBROSIS EXTENSION IN SYSTEMIC SCLEROSIS: A CASE-CONTROL STUDY
A. Tieu, B. Chaigne, B. Dunogue, J. Dion, A. Regent, P. Legendre, C. Le Jeune, L. Mouthon
- P.050** CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS AND CANCER: RESULTS OF THE SPANISH REGISTRY OF SCLERODERMIA (RESCLE)
C. Carbonell, A. Chamorro, P. Segovia Alonso, C. Tolosa Vilella, L. Trapiella Martínez, D. Colunga Argüelles, L. Sáez Comet, M. Rubio Rivas, A. Argibay, A. Madroñero Vuelta, M. Sánchez García, M. Ruiz Muñoz, F. García Hernández, G. Espinosa, J. Ríos Blanco, E. Callejas Moraga, A. Guillén Del Castillo, V. Fonollosa Pla, C. Simeón Aznar, On behalf of Rescle Investigators
- P.051** CO-EXISTENCE OF SSC HALLMARK AUTOANTIBODIES ASSOCIATES WITH DISTINCT CLINICAL PHENOTYPE
C. Campochiaro, K. Clark, L. Host, S. Alper, S. Nihtyanova, C. Denton, V. Ong
- P.052** EVALUATION OF TWO DISTINCT ASSAYS FOR DETECTION OF ANTI-TH/TO ANTIBODIES IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY
E. Callejas-Moraga, J. Perurena-Prieto, A. Guillén-Del-Castillo, L. Viñas-Gimenez, A. Marin-Sánchez, E. Balada-Prades, V. Fonollosa-Plá, M. Sanz-Martinez, M. Mahler, C. Simeón-Aznar
- P.053** COEXISTENCE OF AUTOANTIBODIES IN SYSTEMIC SCLEROSIS: FREQUENCY AND ASSOCIATION WITH CLINICAL CHARACTERISTICS
J. Caetano, F. Paula, M. Amaral, S. Oliveira, J. Delgado Alves
- P.054** THE AP1-TRANSCRIPTION FACTOR C/JUN AND THE HEDGEHOG MEDIATOR GLI2 COOPERATE TO AMPLIFY FIBROBLAST ACTIVATION AND TISSUE FIBROSIS
C. Bergmann, B. Merlevede, L. Hallenberger, C. Dees, C. Chen, T. Trinh-Minh, A. Bozec, G. Schett, J. Distler

- P.055** CLINICAL PREVALENCE OF ANTI-BICD2 ANTIBODIES USING A NOVEL MULTI-ANALYTE ASSAY FOR THE DIAGNOSIS OF SYSTEMIC SCLEROSIS IN A SPANISH COHORT
E. Ruiz-Ortiz, S. Prieto, F. Hernández-González, A. Pérez-Isidro, M. Mahler, S. Casas, C. Bentow, A. Seaman, K. Norvell, M. Tiongson, M. Aure, G. Kim, R. Cervera, O. Viñas, G. Espinosa
- P.056** THE HMGB1/AGE-RAGE AXIS IN PATIENTS WITH SYSTEMIC SCLEROSIS: A POTENTIAL ROLE IN ITS VASCULOPATHY?
I.M. Atzeni, A. Eman Abdulle, A. van Roon, A.J. Smit, G.F. H. Diercks, H. van Goor, J. Westra, D.J. Mulder
- P.057** ABERRANT EXPRESSION LEVELS OF SOLUBLE CO-INHIBITORY RECEPTORS AS MARKERS OF T CELL EXHAUSTION AND DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS
M. Aspari, V. Ong, B. Deleuran, D. Abraham
- P.058** FEATURES OF THE DEBUT OF SYSTEMIC SCLERODERMA ARE ABLE TO DETERMINE THE DISEASE PATTERN
A. Aleksandrov, L. Shilova, V. Aleksandrov
- P.059** A NOVEL HUMANIZED MOUSE MODEL OF SKIN FIBROSIS
G. Moroncini, C. Paolini, F. Orlando, A. Grieco, S. Agarbati, C. Tonnini, S. Svegliati Baroni, T. Spadoni, A. Funaro, E. Avedimento, M. Provinciali, A. Gabrielli
- P.060** THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS
J.E. Oller Rodríguez, M. De La Rubia Navarro, E. Grau García, I. Martínez Cordellat, F.M. Ortiz Sanjuán, E. Vicens Bernabéu, R. Negueroles Albuixech, I. Chalmeta Verdejo, C. Alcañiz Escandell, C. Perales Pávez, C. González Mazarío, J.J. Fragío Gil, I. Cánovas Olmos, C. Nájera Herranz, L. González Puig, J. Ivorra Cortés, J.A. Román Ivorra

PULMONARY INCLUDING INTERSTITIAL LUNG DISEASE AND PULMONARY

- P.061** SYSTEMIC SCLEROSIS AUTO-ANTIBODY PROFILES PREDICT INTERSTITIAL LUNG DISEASE ONSET BUT NOT PROGRESSION
B. Zheng, M. Wang, M.J. Fritzler, M.Y. Choi, M. Baron, M. Hudson, On Behalf of the CSRG
- P.062** TREATMENT WITH MYCOPHENOLATE MOFETIL AND CYCLOPHOSPHAMIDE LEADS TO CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
E. Volkman, D. Tashkin, H. Leclair, M. Roth, P. Clements, G. Kim, J. Goldin, D. Furst, D. Khanna
- P.063** THE MUC5B PROMOTER VARIANT DOES NOT PREDICT RESPONSE TO IMMUNOSUPPRESSION IN PATIENTS WITH SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
E. Volkman, D. Tashkin, N. Li, J. Charles, M. Mayes, M. Roth, G. Kim, J. Goldin, P. Clements, D. Furst, D. Khanna, L. Pourzand, R. Elashoff, S. Assassi
- P.064** FATAL CONSEQUENCES OF THERAPEUTIC THORACENTESIS IN PATIENTS WITH SYSTEMIC SCLEROSIS
L. Vigdorich, A. Natour, O. Wand, Y. Levy

PULMONARY INCLUDING INTERSTITIAL LUNG DISEASE AND PULMONARY

- P.065** QUANTITATIVE CHEST COMPUTED TOMOGRAPHY (QCT) ANALYSIS OF SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED WITH RITUXIMAB: PRELIMINARY FINDINGS
F. Cacciapaglia, S. Parisi, F. Montini, V. Fiore, L. Urso, E. Fusaro, A. Ariani, F. Iannone
- P.066** LUNG FIBROSIS DOES NOT IMPACT PLATELET COUNT IN SCLERODERMA PATIENTS WITH LUNG INVOLVEMENT
Y. Suliman, S. Kafaja, M. Alemam, D. E. Furst
- P.067** SYSTEMIC LEVELS OF S100A4 CORRELATE WITH DISEASE ACTIVITY, SKIN FIBROSIS AND INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS
H. Storkanova, L. Andres Cerezo, S. Oreska, M. Spiritovic, B. Hermankova, M. Komarc, K. Pavelka, J. Vencovsky, J. Distler, R. Becvar, L. Senolt, M. Tomcik
- P.068** EXTRACELLULAR HSP90 AS A POTENTIAL BIOMARKER OF SKIN AND LUNG INVOLVEMENT IN SYSTEMIC SCLEROSIS
H. Storkanova, S. Oreska, M. Spiritovic, B. Hermankova, K. Bubova, M. Komarc, K. Pavelka, J. Vencovsky, J. Distler, L. Senolt, R. Becvar, M. Tomcik
- P.069** PULMONARY HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS – AN AUDIT OF SCREENING PRACTICES AND COST OVER 10 YEARS
L. Spray, J. Vila, B. Griffiths
- P.070** MANAGEMENT AND BURDEN OF DISEASE OF SSC-ILD IN EIGHT EUROPEAN COUNTRIES: RESULTS OF THE BUILDUP PROJECT
W. Wuyts, J. Rømhild Davidsen, M. Kilpeläinen, M. Durheim, S. Papisis, E. Manali, J. Miedema, C. Robalo Cordeiro, A. Morais, M. Perez, G. Asjje, S. Soulard
- P.071** NINTEDANIB INHIBITS GROWTH FACTOR INDUCED FIBROSIS IN AN IN VITRO FIBROBLAST MODEL OF SYSTEMIC SCLEROSIS
A. Siebuhr, M. Karsdal, A. Bay-Jensen, P. Juhl
- P.072** PLEURO-PARENCHYMAL FIBROELASTOSIS IN SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE
A. Sari, O. Onder, B. Armagan, E. Bolek, B. Farisogullari, E. Bilgin, G. Yardimci, M. Ariyurek, A. Akdogan
- P.073** COMPARISON BETWEEN DIFFERENT THERAPEUTICAL APPROACH TO SYSTEMIC SCLEROSIS (SSC) RELATED INTERSTITIAL LUNG DISEASE (ILD)
M. Saracco, T. Oddenino, C. Lomater
- P.074** WHICH TREATMENT ASPECTS MATTER TO PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE? THE DEVELOPMENT OF A PATIENT PREFERENCE INSTRUMENT
L. Saketkoo, C. Bruni, N. Schoof, S. Heidenreich, A. Duenas, M. Alves, A. Hoffmann-Vold, A. Gabrielli, O. Distler
- P.075** PREVALENCE AND SURVIVAL OF SYSTEMIC SCLEROSIS (SSC) AND ASSOCIATED INTERSTITIAL LUNG DISEASE IN ONTARIO, CANADA OVER 10 YEARS
J. Pope, K. Quansah, M. Kolb, J. Flavin, S. Hassan, S. Seung
- P.076** CORRELATION BETWEEN PARAMETERS OF PULMONARY FUNCTION AND ANTI-SCL-70 ANTIBODIES IN THE PATIENTS WITH SSC AND ILD OVER 5 YEAR FOLLOW UP
O. Ovsyannikova, O. Koneva, L. Ananieva, L. Garzanova, O. Desinova, M. Starovoytova
- P.077** ASSOCIATION PROGRESSION PULMONARY ALTERATIONS BY HRCT OF WITH EUROPEAN SCLERODERMA STUDY GROUP ACTIVITY INDEX (ESCSG-AI) IN PATIENTS WITH SYSTEMIC SCLEROSIS OVER A FIVE YEAR PERIOD
O. Ovsyannikova, O. Koneva, L. Ananieva, L. Garzanova, O. Desinova, M. Starovoytova
- P.078** PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS: A NEW TOOL FOR SYSTEMIC SCLEROSIS CLASIFICATION?
F. Ortiz-Sanjuán, C. Alcañiz, I. Cánovas, I. Chalmeta, M. De La Rubia, J. Fraggio, R. González, L. González, E. Grau, S. Leal, I. Martínez, C. Nájera, R. Negueroles, C. Pávez, J. Oller, E. Vicens, J. Ivorra, J. Román-Ivorra
- P.079** FORCED VITAL CAPACITY TRAJECTORIES IN PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY FIBROSIS
S.I. Nihtyanova, E.C. Derrett-Smith, C. Fonseca, V.H. Ong, C.P. Denton
- P.080** ABNORMAL ESOPHAGOGAM PREDICTS PULMONARY FUNCTION DETERIORATION IN PATIENTS WITH SYSTEMIC SCLEROSIS
L. Gigante, E. De Lorenzis, G. Natalello, L. Berardini, Giovanni B. Canestrari, L. Verardi, E. Gremese, L. Richeldi, S. Bosello
- P.081** ESOPHAGEAL EROSIONS PREDICT PROGRESSION OF LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS
E. De Lorenzis, G. Natalello, L. Berardini, Giovanni B. Canestrari, L. Gigante, L. Verardi, E. Gremese, L. Richeldi, S. Bosello
- P.082** OUTCOME OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SCLERODERMA: A 5 YEAR PROSPECTIVE COHORT STUDY
R. Nanavati, R. Samant, A. Khune
- P.083** ANALYSIS OF SERUM CARBOHYDRATE ANTIGENS (CA 19-9, CA 125, CA 15-3), CARCINOEMBRYONIC ANTIGEN AND ALPHA FETOPROTEIN IN SYSTEMIC SCLEROSIS PATIENTS WITH ASSOCIATED INTERSTITIAL LUNG DISEASES (ILD)
C. Naclerio, A. Cavallera, T. Urraro, S. Scarpatò
- P.084** A NEW FUNCTIONAL STAGING OF SSC-RELATED INTERSTITIAL LUNG DISEASE WITH PROGNOSTIC IMPLICATIONS
A. Santaniello, L. Bettolini, C. Bellocchi, M. Cassavia, G. Montanelli, B. Vigone, A. Severino, M. Caronni, C. Campochiaro, E. De Lorenzis, L. Cavagna, G. De Luca, S. Bosello, L. Beretta
- P.085** PREVALENCE AND CLINICAL PRESENTATION OF SSC-ASSOCIATED ILD ACCORDING TO WORLDWIDE SPATIAL REPARTITION IN THE EUSTAR DATABASE
A. Lescoat, D. Huscher, E. Hachulla, C. Denton, M. Matucci-Cerinic, G. Riemekasten, F. Del Galdo, C. Caimmi, M. Truchetet, N. Schoof, O. Distler, Y. Allanore
- P.086** EVALUATION OF THE RITUXIMAB LOW DOSES EFFECT ON SYSTEMIC SCLEROSIS CLINICAL MANIFESTATIONS AND ACTIVITY
O. Koneva, L. Ananyeva, L. Garzanova, O. Desinova, O. Ovsyannikova, M. Starovoytova

PULMONARY INCLUDING INTERSTITIAL LUNG DISEASE AND PULMONARY

- P.087** **EVALUATION OF THE RITUXIMAB MONOTHERAPY EFFICACY IN THE PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE**
O. Koneva, L. Ananyeva, L. Garzanova, O. Desonova, O. Ovsyannikova, M. Starovoytova
- P.088** **USE OF IMMUNOSUPPRESSANTS AND CLINICAL OUTCOMES AMONG PATIENTS WITH SYSTEMIC SCLEROSIS AND SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A US COHORT STUDY**
Q. Li, L. Wallace, P. Patnaik, M. Alves, M. Gahlemann, V. Kohlbrenner, C. Raabe, J.R. Wang, L.M. Garry
- P.089** **DISEASE FREQUENCY AND CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS AND SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A US COHORT STUDY**
Q. Li, L. Wallace, P. Patnaik, M. Alves, M. Gahlemann, V. Kohlbrenner, C. Raabe, Jocelyn R. Wang, E.M. Garry
- P.090** **EFFECT OF NINTEDANIB ON PROGRESSION OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): FURTHER ANALYSES OF THE SENCIS TRIAL**
D. Khanna, D. Furst, M. Aringer, M. Cutolo, I. Castellvi, T. Luckhardt, C. Stock, M. Alves, M. Gahlemann, O. Distler
- P.091** **EVIDENCE-BASED CONSENSUS STATEMENTS FOR THE IDENTIFICATION AND MANAGEMENT OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS**
A. Hoffmann-Vold, T. Maher, A. Ashrafzadeh, O. Distler
- P.092** **PREVENTION OF INTERSTITIAL LUNG DISEASE WITH IMMUNOSUPPRESSIVE THERAPY IN SYSTEMIC SCLEROSIS**
S. Hoa, S. Bernatsky, S. Proudman, W. Stevens, J. Sahhar, M. Wang, Russell J. Steele, M. Baron, M. Nikpour, M. Hudson
- P.093** **ANALYSIS OF SYSTEMIC SCLEROSIS LUNG DISEASE WITH CELLPHONEDB**
M. Hinchcliff, I. Odell
- P.094** **A THIRTEEN-YEAR SINGLE-CENTER EXPERIENCE IN SYSTEMIC SCLEROSIS AND LUNG TRANSPLANTATION**
P. Gubern Prieto, A. Guillén-Del-Castillo, C. Berastegui García, A. Román-Broto, C. Bravo-Masgoret, M. López-Meseguer, I. Bello-Rodríguez, E. Callejas-Moraga, I. Sanz-Pérez, M. Roca-Herrera, V. Fonollosa-Pla, C. Simeón-Aznar
- P.095** **THE ROLE OF NAILFOLD CAPILLAROSCOPY IN MONITORING LUNG INVOLVEMENT IN SYSTEMIC SCLEROSIS**
L. Groseanu, P. Paraschiva, A. Balanescu, V. Bojinca, D. Opris-Belinski, A. Borangiu, I. Saulescu, D. Mazilu, S. Daia-Iliescu, F. Bergheta, C. Constantinescu, M. Negru, M. Abobului, C. Cobilinschi, R. Ionescu
- P.096** **CALIPER: EVALUATION OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS**
G. Leodori, C. Pellicano, A. Villa, A. Iacolare, A. Gigante, A. Ferrazza, M. Gasperini, I. Carbone, E. Rosato
- P.097** **SELF-REPORTED SYSTEMIC SCLEROSIS-RELATED AND PULMONARY SYMPTOMS ARE MORE PREVALENT IN SUBJECTS WITH RAYNAUD'S IN THE GENERAL POPULATION**
A. Eman Abdulle, K. de Leeuw, L. Brouwer, S. Arends, C. Tji Gan, A. Herrick, H. van Goor, U. Mulder
- P.098** **CIRCULATING BIOMARKERS IN INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A META-ANALYSIS**
M. Elhai, J. Avouac, Y. Allanore
- P.099** **SYSTEMIC MICROANGIOPATHY IN PULMONARY ARTERIAL HYPERTENSION: PRELIMINARY DATA FROM A CROSS-SECTIONAL STUDY**
T. Dimitroulas, A. Arvanitaki, G. Giannakoulas, E. Triantafyllidou, C. Feloukidis, P. Rouskas, S. Mouratoglou, H. Karvounis, A. Garyfallos
- P.100** **CORRELATION BETWEEN HRCT SCORE WITH PULMONARY FUNCTION TEST ON SYSTEMIC SCLEROSIS PATIENTS**
A. Sudianto, H. Soekersi, I. Hasan Hikmat, S. Dewi, H. Yani &, I. Desrianda
- P.101** **HAEMOSTATIC FUNCTION AND FIBRIN CLOT PROPERTIES IN PATIENTS WITH SYSTEMIC SCLEROSIS**
J. Colic, A. Antovic, I. Pruner, J. Vojnovic, M. Sekic-Bukilica, N. Damjanov
- P.102** **EVOLUTION OF SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE ONE YEAR AFTER TREATMENT WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CYCLOPHOSPHAMIDE**
J. Ciaffi, N.M. Van Leeuwen, M. Boonstra, L.J.M. Kroft, A.A. Schouffoer, M.K. Ninaber, T.W.J. Huizinga, J.K. De Vries-Bouwstra
- P.103** **EFFECTS OF NINTEDANIB IN PATIENTS WITH EXTENSIVE AND LIMITED SYSTEMIC SCLEROSIS-ASSOCIATED ILD (SSC-ILD): FURTHER ANALYSES OF THE SENCIS TRIAL**
D. Christopher, N. Goh, D. Lynch, T. Maher, V. Smith, V. Cottin, R. Spiera, C. Stock, M. Gahlemann, M. Alves, A. Wells
- P.104** **FOLLOW-UP EVALUATION OF A PROTOCOL-BASED TREATMENT FOR SYSTEMIC SCLEROSIS RELATED-INTERSTITIAL LUNG DISEASE**
J. Caetano, F. Paula, M. Amaral, S. Oliveira, J. Delgado Alves
- P.105** **THE LINK BETWEEN PARENCHYMAL AND VASCULAR FEATURES IN SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSC-ILD): A QUANTITATIVE ANALYSIS OF IMAGING FEATURES AT CHEST CT**
C. Bruni, M. Occhipinti, G. Camiciottoli, M. Bartolucci, M. Pienn, G. Lepri, A. Fabbrizzi, A. Tottoli, G. Ciardi, D. Giuggioli, G. Cuomo, F. Masini, H. Olschewski, F. Lavorini, S. Colagrande, M. Matucci Cerinic
- P.106** **SCREENING TOOLS FOR PULMONARY ARTERIAL HYPERTENSION (PAH) IN SYSTEMIC SCLEROSIS (SSC): A SYSTEMATIC LITERATURE REVIEW (SLR)**
C. Bruni, G. De Luca, M. Lazzaroni, E. Zanatta, M. Matucci Cerinic
- P.107** **CARDIAC CATHETERIZATION VERSUS ECHOCARDIOGRAPHY FOR MONITORING PULMONARY PRESSURE: A PROSPECTIVE STUDY IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION**
V. Bourbia, I. Tsangaris, L. Rallidis, D. Konstantonis, F. Frantzeskaki, A. Anthi, S. Orfanos, E. Demerouti, P. Kariofyllis, V. Voudris, A. Laskari, S. Panopoulos, P. Vlachoyiannopoulos, P. Sfikakis

PULMONARY INCLUDING INTERSTITIAL LUNG DISEASE AND PULMONARY

- P.108** **A SINGLE HUNGARIAN PULMONOLOGY CENTER EXPERIENCE ON SCLERODERMA RELATED INTERSTITIAL LUNG DISEASES**
A. Bohács, K. Vincze, E. Kiss, A. Polgár, Á. Tárnoki, D. Tárnoki, K. Karlócai, K. Karlinger, V. Müller
- P.109** **TREATMENT WITH A THROMBIN INHIBITOR, DABIGATRAN ETEXILATE, REDUCES PROTOTYPIC MARKER OF DIFFERENTIATED MYOFIBROBLASTS IN SCLERODERMA LUNG**
G. Bogatkevich, I. Atanelishvili, R. Silver
- P.110** **EFFECT OF NINTEDANIB ON PROGRESSION OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) OVER 100 WEEKS: DATA FROM THE SENSISC TRIAL**
S. Assassi, O. Distler, Y. Allanore, T. Ogura, J. Varga, S. Vettori, B. Crestani, U. Von Wangenheim, M. Quaresma, M. Alves, S. Stowasser, T. Maher
- P.111** **DLCO IN MONITORING AND MANAGING DISEASE PROGRESSION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE**
C. Ancuta, C. Pomirleanu, R. Paiu, E. Ancuta, T. Cernomaz, R. Chiriac
- P.112** **PROFIBROTIC PROTEINS DOWNSTREAM OF THROMBIN RECEPTOR PAR-1 ARE DECREASED IN LUNG SCLERODERMA FIBROBLASTS FOLLOWING DABIGATRAN TREATMENT**
G.S. Bogatkevich, I. Atanelishvili, R.M. Silver

ARTERIAL HYPERTENSION

- P.113** **SKIN INVOLVEMENT AND PERIPHERAL VASCULAR SYNDROME IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ASSOCIATED PULMONARY ARTERIAL HYPERTENSION**
N. Yudkina, A. Volkov, E. Nikolaeva, I. Kurmukov
- P.114** **SUBTYPE OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS**
N. Yudkina, A. Volkov, E. Nikolaeva, I. Kurmukov
- P.115** **ASSOCIATION BETWEEN IRON STUDIES AND PULMONARY HAEMODYNAMICS IN SYSTEMIC SCLEROSIS**
A. Sari, S.J. Nihtyanova, B.E. Schreiber, G. Coghlan, Christopher P. Denton, V.H. Ong
- P.116** **DELAYED RECOVERY OF ELEVATED PULMONARY ARTERIAL PRESSURE AFTER EXERCISE AS AN EARLY SIGN OF PULMONARY VASCULAR REMODELING LEADING TO PULMONARY HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS**
K. Sakurai, Y. Yamasaki, K. Suzuki, Y. Asari, T. Suzuki, T. Kiyokawa, Y. Akashi, S. Kou, H. Yamada, K. Kawahata
- P.117** **CHANGE IN PHYSICAL FUNCTION IN SYSTEMIC SCLEROSIS PATIENTS WITH INTERMEDIATE/HIGH RISK FOR PULMONARY HYPERTENSION – CLINICAL IMPLICATION OF ENDOTHELIN-RECEPTOR ANTAGONIST TREATMENT**
J. Park, H. Choi, E. Park, H. Kwon, S. Cho, E. Lee
- P.118** **EFFICACY AND SAFETY OF ORAL PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG IN PATIENTS WITH SYSTEMIC SCLEROSIS -ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IN DAILY CLINICAL PRACTICE, A CASE SERIES**
J. Lemmers, H. Fretheim, H. Knaapen-Hans, F. van den Hoogen, J. van Haaren-Willems, T. Duijnhouwer, A. van Dijk, C. van den Ende, A. Hoffmann-Vold, M. Vonk
- P.119** **APPLYING THE PROPOSED DEFINITION FOR PULMONARY HYPERTENSION IN A SYSTEMIC SCLEROSIS COHORT**
D. Langli, H. Fretheim, H. Marjavanja Inseth, Ø. Midtvedt, T. Garen, Ø. Molberg, E. Gude, A. Andreassen, A. Hoffmann-Vold
- P.120** **NAIFOLD CAPILLAROSCOPY PARAMETERS AS PREDICTORS OF PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS**
N. Klyaus, M. Simakova, A. Maslyanskiy, O. Moiseeva
- P.121** **TREATMENT EFFECTS ON OUTCOME IN SYSTEMIC SCLEROSIS PATIENTS WITH MILDLY ELEVATED PULMONARY PRESSURE**
H. Fretheim, D. Langli, H. Inseth, Ø. Midtvedt, T. Garen, Ø. Molberg, E. Gude, Arne K. Andreassen, A. Hoffmann-Vold
- P.122** **EFFICACY OF TARGETED THERAPIES FOR PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH CONNECTIVE TISSUE DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS**
M. Erdogan, S. Esatoglu, V. Hamuryudan, G. Hatemi
- P.123** **COMPARISON OF DIFFERENT PULMONARY HYPERTENSION SCREENING ALGORITHMS IN PATIENTS WITH SYSTEMIC SCLEROSIS**
M. Erdogan, B. Kilickiran Avci, Y. Ersoy, C. Ebrén, Z. Ongen, G. Ongen, V. Hamuryudan, G. Hatemi
- P.124** **SCREENING FOR THE EARLY DETECTION OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC): A META-ANALYSIS OF LONG-TERM OUTCOMES**
Z. Brown, D. Hansen, W. Stevens, S. Proudman, M. Nikpour
- P.125** **RETROSPECTIVE EVALUATION OF THE ASIG AND DETECT ALGORITHMS FOR THE EARLY DETECTION OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN SYSTEMIC SCLEROSIS (SSC)**
Z. Brown, D. Hansen, M. Wilson, L. McWilliams, L. Spargo, J. Walker, W. Stevens, S. Proudman, M. Nikpour
- P.126** **RETROSPECTIVE VALIDATION OF THE ESC/ERS RISK PREDICTION MODEL IN SYSTEMIC SCLEROSIS (SSC) PATIENTS WITH NEWLY DIAGNOSED PULMONARY ARTERIAL HYPERTENSION (PAH)**
Z. Brown, D. Hansen, M. Wilson, J. Roddy, G. Ngjan, J. Sahhar, K. Morrisroe, J. Walker, S. Proudman, W. Stevens, M. Nikpour
- P.127** **FINDINGS OF EXERCISE ULTRASOUND CARDIOGRAPHY IN PRE-PAH PATIENTS WITH SYSTEMIC SCLEROSIS ARE CORRELATED WITH EXTENT OF CAPILLARY LOSS DETECTED BY NAIFOLD VIDEOCAPILLAROSCOPY**
K. Ashihara, T. Naganawa, M. Hoshino, Y. Kato, S. Fukaya, S. Yoshida, H. Yasuoka

CARDIAC

P.128 MEAN PLATELET VOLUME AS A POTENTIAL BIOMARKER OF IMPAIRED RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS

S. Jaksic Jurinjak, S. Tomasinec, M. Lucijanec, D. Delic-Brkljajic, M. Culo, J. Morovic-Vergles

P.129 CORONARY ARTERY CALCIFICATIONS ARE ASSOCIATE TO HEART ARRHYTHMIA BUT NOT TO CARDIOVASCULAR EVENTS IN SYSTEMIC SCLEROSIS PATIENTS

C. Rotondo, S. Sciacca, L. Lops, A. Corrado, F. Cantatore

P.130 FACTORS ASSOCIATED WITH CARDIAC INVOLVEMENT IN SYSTEMIC SCLEROSIS. EVALUATION IN A COHORT OF 139 PATIENTS

A. Raschia, P. Sansinanea, M. Martire, L. Garcia

P.131 RIGHT HEART CATHETERISATION AND CARDIAC MAGNETIC RESONANCE IMAGING FINDINGS IN SYSTEMIC SCLEROSIS PATIENTS REFERRED FOR AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT

R. Penglase, A. Jabbour, E. Kotlyar, L. Girgis, D. Ma, J. Moore

P.132 ELECTROCARDIOGRAPHIC ABNORMALITIES AND PULMONARY INVOLVEMENT IN A MONOCENTRIC COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS

G. Pellegrino, F. Facioni, K. Stefanantonio, C. Angelelli, C. Vizza, R. Badagliacca, S. Morelli, G. Valesini, V. Ricciari

P.133 ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES IN SYSTEMIC SCLEROSIS, A CLUE FOR PRIMARY HEART INVOLVEMENT

G. Natalello, G. De Luca, Giovanni B. Canestrari, E. De Lorenzis, C. Campochiario, L. Gigante, L. Verardi, B. Tolusso, E. Gremese, L. Dagna, S. Bosello

P.134 THE ROLE OF CARDIOPULMONARY EXERCISE TEST (CPET) FOR DETECTING PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS PATIENTS

L. Litinsky, A. Man, D. Paran, S. Borok, M. Berman, U. Arad, M. Anouk, R. Zemach, O. Elkayam

P.135 EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN THE TREATMENT OF SYSTEMIC SCLEROSIS-RELATED MYOCARDITIS: A RETROSPECTIVE STUDY FROM IRANIAN SYSTEMIC SCLEROSIS REGISTRY

H. Kavousi, Z. Javadi Nejad, A. Javini, A. Jamshidi, Z. Tamartash, F. Gharibdoost

P.136 NON-INVASIVE CARDIAC IMAGING TECHNIQUES FOR THE EVALUATION OF THE CARDIOVASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS

A. Guillen-Del-Castillo, C. Espinet, M. Pizzi, A. Roque, V. Pineda, I. Sanz, E. Callejas-Moraga, P. Gubern, S. Aguade, V. Fonollosa, C. Simeón-Aznar

P.137 MYOCARDIAL FIBROSIS IN SYSTEMIC SCLEROSIS ASSESSED BY CARDIAC MAGNETIC RESONANCE IS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION

G. Leodori, C. Pellicano, V. Anna Lisa, A. Iacolare, A. Gigante, N. Galea, M. Gasperini, I. Carbone, E. Rosato

P.138 ASSOCIATED FACTORS OF EARLY-ONSET PULMONARY HYPERTENSION AND CLINICAL DIFFERENCE BETWEEN EARLY- AND LATE-ONSET PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS

C. Foocharoen, T. Krikeerati, B. Pussadhamma, A. Mahakkanukrauh, S. Suwannaroj, R. Nanagara

P.139 CLINICAL OUTCOMES OF MYOCARDITIS AFTER STEROID THERAPY IN SYSTEMIC SCLEROSIS: A PILOT STUDY

C. Foocharoen, B. Pussadhamma, N. Chaosuwannakit, T. Tipparot, A. Mahakkanukrauh, S. Suwannaroj, R. Nanagara

P.140 SYSTEMIC SCLEROSIS IS ASSOCIATED WITH IMPAIRED CORONARY FLOW RESERVE ON 82-RUBIDIUM POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY

A. Feher, N. Boutagy, E. Oikonomou, S. Thorn, Y. Liu, E. Miller, A. Sinusas, M. Hinchcliff

P.141 DECLINE IN SUBCLINICAL SYSTEMIC SCLEROSIS PRIMARY HEART INVOLVEMENT ASSOCIATES WITH POOR PROGNOSTIC FACTORS AND ACTIVE INTERSTITIAL LUNG DISEASE

R. Dumitru, L. Bissell, B. Erhayiem, G. Fent, A. Kidambi, G. Abignano, John P. Greenwood, J. Biglands, F. Del Galdo, S. Plein, M. Buch

P.142 PROGRESSION OF SUBCLINICAL MYOCARDIAL INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS

D. Benfaremo, L. Manfredi, L. Zuliani, G. Stronati, F. Guerra, A. Ferrarini, C. Fischetti, M. Danieli, A. Capucci, A. Gabrielli

P.143 ROLE OF RIGHT VENTRICULAR STRAIN AND 2D-SPECKLE TRACKING ECHOCARDIOGRAPHY IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS

A. Spinella, P. Macripò, E. Cocchiara, E. Galli, F. Lumetti, L. Magnani, F. Coppi, A. Mattioli, R. Rossi, G. Boriani, C. Salvarani, D. Giuggioli

P.144 SUCCESSFUL TAVI PROCEDURE FOR REPAIR OF AORTIC STENOSIS IN SSC PATIENTS

A. Balbir Gurman, A. Kerner, Y. Agmon, Y. Braun-Moscovici

OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

P.145 THE CLINICAL CHARACTERISTICS OF SYSTEMIC SCLEROSIS WITH LUNG CANCER: DATA FROM SINGLE CENTER IN CHINA

H. Zhong, J. Zhou, S. Zhang, Y. Xu, Y. Hou, M. Li, D. Xu, M. Wang, X. Zeng

P.146 DEVELOPMENT OF A PATIENT-CENTRED ILOPROST AND ALPROSTADIL INFUSION INFORMATION SHEET FOR PATIENTS WITH SYSTEMIC SCLEROSIS

M. Yelovich, K. Beattie, A. Gardner, C. Whisken, N. Khalidi, M. Larche

P.147 THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND SEVERITY IN SYSTEMIC SCLEROSIS: A PROSPECTIVE ANALYSIS OF 278 PATIENTS

Y. Yalcinkaya, N. Aliyeva, S. Amikishiyev, Y. Çagatay, B. Artim Esen, A. Gul, L. Ocal, M. Inanc

OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

- P.148** **EVALUATION OF DIFFERENT CLASSIFICATION CRITERIA IN SYSTEMIC SCLEROSIS IN A TURKISH COHORT: THE IMPORTANCE OF NON-SKIN MANIFESTATIONS, SEROLOGY AND CAPILLAROSCOPY**
Y. Yalcinkaya, S. Amikishiyev, N. Aliyeva, B. Artim Esen, A. Gul, L. Ocal, M. Inanc
- P.149** **DIFFERENCES BETWEEN LATE AND EARLY-ONSET SYSTEMIC SCLEROSIS**
E. Wielosz, M. Dryglewska, M. Majdan
- P.150** **THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK – SCLERODERMA SUPPORT GROUP LEADER EDUCATION (SPIN-SSLED) PROGRAM: NON-RANDOMISED FEASIBILITY TRIAL**
B. Thombs, L. Dyas, M. Pépin, K. Aguilá, M. Carrier, L. Tao, S. Harb, V. Malcarne, G. El-Baalbaki, S. Peláez, M. Sauve, M. Hudson, R. Platt
- P.151** **PERCEIVED BARRIERS AND FACILITATORS OF USING SYNCHRONOUS TELEREHABILITATION OF PHYSICAL AND OCCUPATIONAL THERAPY IN MUSCULOSKELETAL DISORDERS: A SCOPING REVIEW**
L. Tao, L. Kwakkenbos, A. Carboni-Jiménez, K. Turner, K. Aguilá, J. Boruff, S. Ahmed, B. Thombs
- P.152** **CHARACTERISTICS OF CRP POSITIVE SYSTEMIC SCLEROSIS (SSC)**
K. Takagi, Y. Kawaguchi, T. Higuchi
- P.153** **RELIABILITY OF WORLD SCLERODERMA FOUNDATION (WSF) DEFINITION OF SKIN ULCERS IN SCLERODERMA, RESULTS FROM THIRD CONSENSUS MEETING**
Y. Suliman, C. Bruni, E. Praino, D. Khanna, Y. Allanore, A. L. Herrick, C. Denton, M. Matucci-Cerinic, D.E. Furst
- P.154** **ENERGY LEVEL: AN OVERLOOKED FACTOR IN ASSESSMENT OF SCLERODERMA PATIENTS**
Y. Suliman, S. Kafaja, M. Alemam, D.E. Furst
- P.155** **HOW DO PATIENTS WITH SYSTEMIC SCLEROSIS EXPERIENCE CURRENTLY PROVIDED HEALTH CARE AND HOW SHOULD WE MEASURE ITS QUALITY?**
J. Spierings, C. Van Den Ende, R. Schriemer, H. Bernelot Moens, E. Van Der Bijl, F. Bonte-Mineur, M. De Buck, M. De Kanter, H. Knaapen-Hans, J. Van Laar, U. Mulder, J. Potjewijd, L. De Punder, T. Schoonbrood, A. Schouffoer, A. Stel, W. Vercoutere, A. Voskuyl, J. De Vries-Bouwstra, M. Vonk
- P.156** **TREATMENT DECISION-MAKING IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A PATIENT'S PERSPECTIVE**
J. Spierings, F. Van Rhijn-Brouwer, C. De Bresser, P. Mosterman, A. Pieterse, M. Vonk, A. Voskuyl, J. De Vries-Bouwstra, M. Kars, J. Van Laar
- P.157** **REVIEW OF MALIGNANCIES IN OUR WAIKATO COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS**
K. Solanki, M. Rees, C. Frampton, D. White
- P.158** **HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI) AND PATIENT GLOBAL ASSESSMENT OF HEALTH (PTGA) CORRELATE WITH CHANGES IN PATIENT-REPORTED OUTCOMES (PROS)**
R. Spiera, L. Hummers, L. Chung, T. Frech, R. Domsic, V. Hsu, D. Furst, J. Gordon, M. Mayes, R. Simms, E. Lee, S. Constantine, B. Conley, Q. Dinh, B. Bloom, B. White
- P.159** **PATIENT AND PHYSICIAN OPINIONS OF CLINICAL BENEFIT AT 3 MONTHS IN A CLINICAL TRIAL CORRELATE WITH PATIENT-REPORTED OUTCOMES (PROS)**
R. Spiera, L. Hummers, L. Chung, T. Frech, R. Domsic, V. Hsu, D. Furst, J. Gordon, M. Mayes, R. Simms, E. Lee, S. Constantine, B. Conley, Q. Dinh, B. Bloom, B. White
- P.160** **CHANGES IN INITIAL CLINICAL PRESENTATIONS OF SYSTEMIC SCLEROSIS OVER 25 YEARS OF OBSERVATION**
V. Semenov, I. Molokova, T. Lysunets, O. Kuryata
- P.161** **DESIGNING DUTCH RECOMMENDATIONS ON NONPHARMACOLOGIC INTERVENTIONS FOR PATIENTS WITH SYSTEMIC SCLEROSIS**
M. Schriemer, J. Spierings, C. Van Den Ende, L. De Punder, M. Vonk, J. De Vries-Bouwstra, S. Dittmar
- P.162** **CONCURRENT AUTOIMMUNE DISORDERS AND THEIR IMPACT ON CLINICAL PRESENTATION IN A COHORT OF SYSTEMIC SCLEROSIS PATIENTS**
C. Rotondo, A. Corrado, G. Bellantuono, F. Cantatore
- P.163** **STUDY OF THE EPIDEMIOLOGICAL, CLINICAL AND ANALYTICAL CHARACTERISTICS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND CANCER IN VALL D'HEBRON HOSPITAL**
M. Roca, A. Guillén, E. Callejas, D. Bernal, J. Hernando, P. Gubern, I. Sansano, J. Perurena, M. Sanz, J. Taberno, V. Fonollosa, C. Simeón
- P.164** **TRAJECTORIES OF PAIN IN SYSTEMIC SCLEROSIS**
R. Wojcik, L. Kwakkenbos, M. Carrier, Donald E. Bailey, M. Knisely, Tamara J. Somers, S. Bartlett, J. Pope, W.R. Nielson, K. Nielson, B.D. Thombs, S. Silva and the SPIN Investigators
- P.165** **LOWER MORTALITY RATE BUT COMPARABLE CLINICAL CHARACTERISTICS OF SYSTEMIC SCLEROSIS IN CRETE-GREECE AS COMPARED TO OTHER EUROPEAN COUNTRIES**
A. Repa, S. Pitsigavdaki, A. Molla Ismail Sali, N. Kougkas, M. Terixaki, N. Avgoustidis, P. Sidiroopoulos, G. Bertsiaris
- P.166** **ASSESSMENT OF THE ACCURACY OF USING ICD-10 CODES TO IDENTIFY SYSTEMIC SCLEROSIS**
S. De Almeida Chaves, H. Derumeaux, P. Do Minh, M. Lapeyre-Mestre, G. Moulis, G. Pugnet
- P.167** **TREATMENT MODALITIES AND DRUG SURVIVAL IN A SYSTEMIC SCLEROSIS REAL –LIFE PATIENT COHORT**
S. Panopoulos, K. Chatzidionysiou, M. Tektonidou, A. Drosos, N. Lioussis, T. Dimitroulas, L. Sakkas, D. Boumpas, P. Voulgari, D. Daoussis, K. Thomas, G. Georgiopoulos, G. Vosvotekas, G. Bertsiaris, P. Sidiropoulos, D. Vassilopoulos, P. Sfikakis
- P.168** **PREVALENCE, SEVERITY AND CLINICAL CORRELATES OF SYMPTOMS OF AUTONOMIC DYSFUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS**
P. Ostojic, M. Atanaskovic Popovic, M. Vujovic, M. Perovic
- P.169** **TOLERABILITY AND SAFETY OF ACETYLSALICYLIC ACID IN PATIENTS WITH SYSTEMIC SCLEROSIS**
L. Verardi, E. De Lorenzis, G. Natalello, G.B. Canestrari, L. Gigante, E. Gremese, S. Bosello

OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

- P.170** **PATIENT-LEVEL EVALUATION OF COMPONENTS OF THE ACR COMBINED RESPONSE INDEX IN SYSTEMIC SCLEROSIS (CRISS) USING PATIENT-REPORTED ANCHORS**
V. Nagaraja, J. Powers, C. Lin, V. Berrocal, D. Khanna
- P.171** **A LATE ONSET OF SYSTEMIC SCLEROSIS IS ASSOCIATED WITH A MORE RAPIDLY PROGRESSING CLINICAL PHENOTYPE - DATA OF THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS**
P. Moinzadeh, S. Hamacher, E. Siegert, U. Mueller-Ladner, G. Riemekasten, C. Guenther, I. Koetter, J. Henes, N. Blank, G. Zeidler, C. Pfeiffer, A. Juche, I. Jandova, J. Ehrchen, M. Schmalzing, L. Susok, T. Schmeiser, C. Sunderkoetter, J.H.W. Distler, N. Hunzelmann
- P.172** **DECREASED ORAL APERTURE IS A POOR PROGNOSTIC FACTOR IN SYSTEMIC SCLEROSIS**
T. Minier, V. Lóránd, Z. Bálint, D. Komjáti, B. Németh, K. Filipánits, A. Kovács, G. Nagy, C. Varjú, L. Czirják, G. Kumánovics
- P.173** **THE RELATIONSHIP OF PATIENT SOCIODEMOGRAPHIC AND SCLERODERMA DISEASE CHARACTERISTICS WITH SOCIAL INTERACTION ANXIETY: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK COHORT STUDY**
A. Meier, S. Gholizadeh, B. Ataseven, S. Roesch, M. Carrier, L. Kwakkenbos, B. Thombs, V. Malcarne, K. Gottesman
- P.174** **THE IMPORTANCE OF A SYSTEMIC SCLEROSIS CLINIC IN A TERTIARY REFERRAL CENTER**
P. Martins, E. Dourado, J. Fonseca, I. Cordeiro, C. Resende
- P.175** **RELATIONSHIP BETWEEN DISEASE ACTIVITY/SEVERITY/DAMAGE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH LOCALIZED SCLERODERMA: A CROSS-SECTIONAL STUDY**
A. Lis-Swiety, A. Skrzypek-Salamon, I. Ranosz-Janicka, L. Brzezinska-Wcislo
- P.176** **DEVELOPMENT AND EVALUATION OF A PATIENT DECISION AID FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SYSTEMIC SCLEROSIS**
L. Kwakkenbos, M. Hudson, L. Schraven, J. Thonen-Velthuisen, B. Thombs
- P.177** **REASONS FOR NOT PARTICIPATING IN SCLERODERMA PATIENT SUPPORT GROUPS: A COMPARISON OF RESULTS FROM THE NORTH AMERICAN AND EUROPEAN SCLERODERMA SUPPORT GROUP SURVEYS**
L. Kwakkenbos, A. Carboni-Jiménez, M. Carrier, M. Pépin, S. Peláez, V. Malcarne, G. El-Baalbaki, B. Thombs
- P.178** **MARKERS OF COLLAGEN TURNOVER ARE ALTERED IN PATIENTS WITH VERY EARLY SYSTEMIC SCLEROSIS: EARLY MARKERS OF TISSUE CHANGES**
R. Dobrota, S. Jordan, P. Juhl, B. Maurer, L. Wildi, A. Bay-Jensen, M. Karsdal, A. Herrick, J. Distler, Y. Allanore, A. Hoffmann-Vold, A. Siebuhr, O. Distler
- P.179** **TYPE III AND TYPE IV COLLAGEN BIOMARKERS PREDICT PROGRESSION OF FIBROSIS IN SYSTEMIC SCLEROSIS**
R. Dobrota, S. Jordan, P. Juhl, B. Maurer, L. Wildi, A. Bay-Jensen, M. Karsdal, A. Herrick, Jörg H.W. Distler, Y. Allanore, A. Hoffmann-Vold, A. Siebuhr, O. Distler
- P.180** **EPIDEMIOLOGY OF EMPLOYMENT OUTCOMES IN SYSTEMIC SCLEROSIS. A SYSTEMATIC REVIEW**
J. Lee, K. Devakandan, M. Anderson, M. Gignac, S. Johnson
- P.181** **GASTROINTESTINAL SYMPTOM BURDEN AND QUALITY OF LIFE IN SYSTEMIC SCLEROSIS: UNDERSTANDING THE ROLE OF DIET**
K. Jensen, L. Wang, R. Kovacic, M. Kowalczyk-Lammi, L. Saketkoo
- P.182** **A SYSTEMATIC REVIEW OF INFORMATION AVAILABLE ON THE INTERNET FOR INDIVIDUALS WITH RAYNAUD'S PHENOMENON AND PATIENTS WITH SYSTEMIC SCLEROSIS**
V. Devgire, A. Martin, R. Sandler, M. Hughes
- P.183** **ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC SCLEROSIS –QUANTITATIVE ANALYSIS OF SOCIODEMOGRAPHIC, CLINICAL AND PSYCHOLOGICAL INFLUENCING FACTORS**
S. Heyne, E. Haufe, J. Szepletowski, R. Reszke, S. Abraham, S. Beissert, J. Schmitt, C. Günther
- P.184** **DOES SCLERODERMA HAVE AN IMPACT ON SEXUAL FUNCTION AND PELVIC FLOOR FUNCTION? A CROSS-SECTIONAL STUDY IN 80 WOMEN WITH SYSTEMIC SCLEROSIS**
B. Hermankova, S. Oreska, H. Storkanova, M. Spiritovic, K. Bubova, H. Smucrova, P. Cesak, K. Pavelka, L. Senolt, J. Vencovsky, R. Becvar, M. Tomcik
- P.185** **ERECTILE DYSFUNCTION AND SEXUAL HEALTH IN MEN WITH SYSTEMIC SCLEROSIS**
B. Hermankova, S. Oreska, H. Storkanova, M. Spiritovic, K. Bubova, H. Smucrova, P. Cesak, K. Pavelka, L. Senolt, J. Vencovsky, R. Becvar, M. Tomcik
- P.186** **INVESTIGATING DIFFERENTIAL ITEM FUNCTIONING ON THE SOCIAL APPEARANCE ANXIETY SCALE FOR FRENCH- AND ENGLISH-SPEAKING PATIENTS: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK COHORT STUDY**
S. Sommer, D. Harel, S. Mills, L. Kwakkenbos, M. Carrier, S. Gholizadeh, A. Portales, K. Nielson, S. Bartlett, V. Malcarne, B. Thombs
- P.187** **USE OF A COHORT-BASED SURVEY TO IDENTIFY IMPORTANT BARRIERS AND FACILITATORS TO PHYSICAL ACTIVITY FOR PEOPLE WITH SCLERODERMA: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK COHORT STUDY PROTOCOL**
S. Harb, S. Peláez, B.D. Thombs, I. Shrier, S. Patient Advisory Team
- P.188** **IDENTIFYING BARRIERS AND FACILITATORS TO PHYSICAL ACTIVITY FOR PEOPLE WITH SCLERODERMA: A NOMINAL GROUP TECHNIQUE STUDY**
S. Harb, J. Cumin, D.B. Rice, S. Peláez, M. Hudson, S.J. Bartlett, A. Roren, D. E. Furst, Tracy M. Frech, C. Nguyen, W.R. Nielson, B.D. Thombs, I. Shrier, S. Patient Advisory Team
- P.189** **A POSTER TO EXPLAIN TO THE PATIENT THE MAIN SIGNS AND SYMPTOMS OF EARLY SSC: RESULTS FROM A GP CLINIC**
P. Pucci, L. Salvi, L. Paganelli, C. Fantauzzo, G. Gambardella, S. Bellando Randone, M. Matucci Cerinic, S. Guiducci
- P.190** **THE NURSE-PATIENT RELATIONSHIP: ANIMAL ASSISTED INTERVENTION (AAI) AS A FACILITATOR**
G. Fiori, T. Pucci, M. Zolferino, E. Corsi, A. Bartoli, D. Buttram, M. Matucci Cerinic, S. Guiducci

OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

- P.191** **DISEASE ACTIVITY INDICES IN SYSTEMIC SCLEROSIS- OLD OR NEW?**
L. Groseanu, S. Petrescu, A. Balanescu, D. Opris-Belinski, F. Berghea, V. Bojnicu, A. Borangiu, I. Saulescu, D. Maziliu, S. Daia-Iliecu, C. Constantinescu, M. Negru, M. Abobului, C. Coblinschi, R. Ionescu
- P.192** **THE INFLUENCE OF BIOFEEDBACK COURSE ON THE QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC SCLEROSIS**
R. Grekhof
- P.193** **INFLUENCE OF PATIENT REPORTED "ARTHRITIS ACTIVITY" IN DETERMINING SHAQ, HAQ-DI AND COCHIN SCORES IN SYSTEMIC SCLEROSIS**
K. Gjeloshi, F. Danzo, G. Abignano, A. Dean, F. Masini, G. Cuomo, F. Del Galdo
- P.194** **A TIME SERIES ANALYSIS OF AIR QUALITY AND THE NUMBERS OF HOSPITALIZATION IN THAI SYSTEMIC SCLEROSIS PATIENTS**
C. Foocharoen, U. Peansukwech, P. Pongkulkiat, A. Mahakkanukrauh, S. Suwannaroj
- P.195** **EFFECT OF SEASON ON THE CLINICAL OUTCOMES OF THAI SYSTEMIC SCLEROSIS: AN ANALYSIS OF A NATIONWIDE THAILAND HEALTHCARE DATABASE**
C. Foocharoen, U. Peansukwech, P. Pongkulkiat, A. Mahakkanukrauh, S. Suwannaroj
- P.196** **FATIGUE IN A SERIES OF CANADIAN PATIENTS WITH SCLERODERMA**
A. Fernandez-Codina, M. Kazem, Z. Jiang, J. Pope
- P.197** **A RETROSPECTIVE ANALYSIS OF CHRONIC USE OF INTRAVENOUS PROSTACYCLIN ANALOGUES IN THE TREATMENT OF RAYNAUD'S PHENOMENON: LIMITED LONG-TERM EFFICACY**
T. Elling, A. Abdulle, A.M. Van Roon, A.J. Stel, D.J. Mulder
- P.198** **SYSTEMIC SCLEROSIS IN PATIENTS AGED LESS AND MORE THAN 60 YEARS - CLINICAL CHARACTERISTIC**
M. Dryglewska, E. Wielosz, A. Lipska, M. Majdan
- P.199** **PATHWAY TO SCLERODERMA: CONCERNING PATIENTS' EXPERIENCES DURING THE DIAGNOSTIC PROCESS**
P. Fennell, L. Shapiro, N. Dorr, R. Lukaszewicz, F. Houser, M. Taylor
- P.200** **THE DIAGNOSIS OF SCLERODERMA AS A TRAUMATIC EXPERIENCE: PATIENTS' REACTIONS TO THE DIAGNOSTIC PROCESS**
P. Fennell, L. Shapiro, N. Dorr, R. Lukaszewicz, F. Houser, M. Taylor
- P.201** **CLINICAL SIGNIFICANCE OF COGNITIVE IMPAIRMENT AND MALNUTRITION IN PATIENTS WITH SYSTEMIC SCLEROSIS**
L. Manfredi, D. Benfaremo, G. Silvi, A. Gabrielli
- P.202** **SCLERODERMA PROGRESSION AND PREGNANCY: A HOPEFUL MESSAGE FROM THE CANADIAN SCLERODERMA RESEARCH GROUP**
S. Deshauer, M. Junek, K. Beattie, M. Larche
- P.203** **A META-ANALYSIS TO DETERMINE THE KEY FACTORS PREDICTING SKIN SCORE REGRESSION IN SYSTEMIC SCLEROSIS CLINICAL TRIALS**
A. Degachi, J. Avouac, Y. Allanore
- P.204** **CURRENT PATIENT REPORTED OUTCOMES (PROS) POORLY REFLECT CHANGES IN LUNG FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS**
F. Danzo, K. Gjeloshi, G. Abignano, A. Dean, F. Masini, G. Cuomo, F. Del Galdo
- P.205** **LUNG FUNCTION IS ASSOCIATED WITH EQ-5D CHANGES OVER TIME IN PATIENTS WITH SYSTEMIC SCLEROSIS**
J. Ciaffi, N.M. Van Leeuwen, M.K. Ninaber, T.W.J. Huizinga, J.K. De Vries-Bouwstra
- P.206** **PREDICTORS OF PERCEIVED FUNCTIONAL STATUS IN EARLY SYSTEMIC SCLEROSIS: A PROSPECTIVE LONGITUDINAL STUDY OF THE GENISOS COHORT**
J. Chernis, M. Buni, S. Kazzaz, J. Ying, S. Assassi, M. Mayes
- P.207** **RANDOMIZED FEASIBILITY TRIAL OF THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK SELF- MANAGEMENT (SPIN-SELF) PROGRAM**
M. Carrier, L. Kwakkenbos, W.R. Nielson, C. Fedoruk, K. Nielson, K. Milette, J. Pope, T. Frech, S. Gholizadeh, L. Hummers, S.R. Johnson, P. Piotrowski, L. Jewett, J. Gordon, L. Chung, D. Bilsker, K. Turner, J. Cumin, J. Welling, M. Sauve, T. Rodriguez Reyna, M. Hudson, M. Larche, S.J. Bartlett, V. L. Malcarne, M.D. Mayes, I. Boutron, L. Mouthon, F. Wigley, B.D. Thombs
- P.208** **DISABILITY AND HIGH COSTS - TWO IMPORTANT ISSUES IN SYSTEMIC SCLEROSIS**
A. Cardoneanu, A. Burlui, E. Rezus
- P.209** **PERCEIVED BURDEN AMONG INFORMAL CAREGIVERS OF PERSONS WITH SYSTEMIC SCLEROSIS COMPARED TO OTHER CHRONIC MEDICAL CONDITIONS: A SYSTEMATIC REVIEW**
A. Carboni-Jimenez, D.B. Rice, M. Cañedo-Ayala, B. Levis, M. Imran, M. Chiovitti, B.D. Thombs
- P.210** **NEUTROPHIL TO LYMPHOCYTE RATIO VARIATIONS IN PATIENTS DECEASED WITH SYSTEMIC SCLEROSIS**
V. Bernardino, A. Rodrigues, M. Fernandes, A. Lladó, A. Panarra
- P.211** **NEUTROPHIL TO LYMPHOCYTE RATIO AND SYSTEMIC SCLEROSIS CLINICAL IMPACT**
V. Bernardino, A. Rodrigues, M. Fernandes, A. Lladó, A. Panarra
- P.212** **THE ROLE OF DIFFERENT SIGNS ON THE EVOLUTION OF RAYNAUD'S PHENOMENON (RP) PATIENTS TO DEFINITE SYSTEMIC SCLEROSIS (SSC): RESULTS FROM AN INTERNATIONAL MULTICENTRE STUDY ON VERY EARLY DIAGNOSIS OF SYS**
S. Bellando Randone, G. Lepri, D. Huscher, T. Minier, C. Bruni, Dan E. Furst, L. Czirkak, M. Cutolo, V. Smith, J. Avouac, S. Guiducci, Y. Allanore, O. Distler, M. Matucci-Cerinic
- P.213** **THE INFLUENCE OF SKIN CALCINOSIS ON THE PROGNOSIS OF DIGITAL ULCERS IN PATIENTS WITH SSC**
V. Venturini, S. Barsotti, M. Di Battista, A. Della Rossa, M. Mosca
- P.214** **DEPRESSION IN SCLERODERMA PATIENTS, SYSTEMATIC REVIEW**
A. Balbir Gurman, D. Israeli-Cohen, Y. Braun-Moscovici
- P.215** **SERUM LEVELS OF VITAMIN D AND THE RELATIONSHIP WITH DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC SCLEROSIS**
C. Pomirleanu, A. Jitaru, E. Ancuta, R. Chiriac, C. Ancuta

OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

- P.216 CAUSES OF MORTALITY IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS**
M. Aguilar Zamora, L. Montolio Chiva, A. Orenes Vera, I. Vazquez Gomez, E. Valls Pascual, D. Ybáñez García, A. Martínez-Ferrer, A. Sendra García, I. Torner Hernández, V. Nuñez Monje, J. Alegre Sancho
- P.217 HAND IMPAIRMENT IN SYSTEMIC SCLEROSIS IN THE PATIENTS FROM THE REPUBLIC OF MOLDOVA**
S. Agachi, L. Groppa, E. Deseatinicova, S. Popa, L. Dutca

IMAGING

- P.218 FAST TRACK ALGORITHM*: HOW TO DIFFERENTIATE A "SCLERODERMA PATTERN" FROM A "NON-SCLERODERMA PATTERN"**
V. Smith, A. Vanhaecke, A.L. Herrick, O. Distler, M.G. Guerra, C.P. Denton, E. Descheppe, I. Foeldvari, M. Gutierrez, E. Hachulla, F. Ingegnoli, S. Kubo, U. Mueller-Ladner, V. Riccieri, A. Sulli, J.M. van Laar, M.C. Vonk, U.A. Walker, M. Cutolo
- P.219 ASSESSING SKIN STIFFNESS IN SYSTEMIC SCLEROSIS THROUGH SHEAR-WAVE ELASTOGRAPHY: A FIVE-YEAR FOLLOW-UP STUDY**
T. Santiago, M. Santiago, M. Salvador, J. P. Da Silva
- P.220 EVALUATING USE OF T1-MOLLI MAPPING IN ASSESSING SYSTEMIC SCLEROSIS CARDIAC INVOLVEMENT**
S. Ng, S. Marchesseau, J. Allen, J. Totman, A. Low
- P.221 PROGNOSTIC ROLE OF CARDIAC MAGNETIC RESONANCE IN SYSTEMIC SCLEROSIS PATIENTS WITH PRIMARY HEART INVOLVEMENT, A FOLLOW-UP STUDY**
 G. B. Canestrari, G. De Luca, E. De Lorenzis, G. Natalello, L. Gigante, L. Verardi, F.A. Gabrielli, R. Marano, E. Gremese, S. Bosello
- P.222 USING DEEP LEARNING IN OPTOACOUSTIC AND OPTICAL NAILFOLD CAPILLAROSCOPY IMAGES TO DIFFERENTIATE BETWEEN PATIENTS WITH SSC AND CONTROLS**
 S. Nitkunanantharajah, K. Haedicke, T. Moore, J. Manning, G. Dinsdale, M. Berks, D. Jüstel, V. Ntziachristos, C. Taylor, M. Dickinson, A. Herrick, A. Murray
- P.223 WHICH NON-INVASIVE TECHNIQUES CAN BEST BE USED TO IMAGE CALCINOSIS?**
 T. Moore, E. Marjanovic, J. Manning, G. Dinsdale, S. Wilkinson, M. Dickinson, A. Herrick, A. Murray
- P.224 IMAGING THE STRUCTURE AND FUNCTION OF SYSTEMIC SCLEROSIS-RELATED TELANGIECTASES; A FEASIBILITY STUDY**
 E. Marjanovic, T. Moore, J. Manning, G. Dinsdale, S. Wilkinson, M. Dickinson, A. Herrick, A. Murray
- P.225 INFRARED THERMOGRAPHY FOR DIAGNOSTIC MANAGEMENT OF MICROVASCULOPATHY IN SYSTEMIC SCLEROSIS: IS IT A GOOD ALTERNATIVE FOR NAILFOLD VIDEOCAPILLAROSCOPY?**
B. Miziolek, A. Lis-Swiety, A. Skrzypek-Salamon, L. Brzezinska-Wcislo
- P.226 THYROID DISORDERS IN PATIENTS WITH SYSTEMIC SCLEROSIS: BIOCHEMICAL AND SONOGRAPHIC CHARACTERISTICS**
K. Meridor, P. Rotman-Pikielny, M. Werner, Y. Levy
- P.227 SYSTEMIC SCLEROSIS- SPECTRUM DISEASES ELUCIDATED BY NAILFOLD VIDEOCAPILLAROSCOPY PATTERNS AND DIGITAL OCCLUSIVE ARTERIAL DISEASE WITH LASER DOPPLER FLOWMETRY**
A. Makol, Y. Radwan, T. Gunderson, C. Crowson, A. Hinze, D. Liedl, P. Wennberg, K. Warrington
- P.228 DIAGNOSTIC PERFORMANCES OF HAND ULTRASOUND PARAMETERS AND THEIR IMPACT ON THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS**
 M. de Saint Riquier, A. Ballerie, F. Robin, N. Belhomme, C. Cazalets, C. Droitcourt, A. Perdriger, C. Yelnik, E. Hachulla, V. Sobanski, P. Jeco, G. Coiffier, A. Lescoat
- P.229 DIAGNOSING SYSTEMIC SCLEROSIS WITH PHOTOACOUSTIC AND HIGH-FREQUENCY ULTRASOUND IMAGING**
 B. Kersten, K. Daoudi, C. De Korte, F. Van Den Hoogen, E. Van Den Ende, M. Vonk
- P.230 ULTRASOUND MEASUREMENT OF THE NAIL BED MATRIX THICKNESS AS A USEFUL MARKER FOR SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE**
V. Hsu, M. Sidor, R. Zuckerman, N. Schlesinger, R. Sussman, S. Huma
- P.231 DIGITAL ARTERY VOLUME INDEX (DAVIX®) PREDICTS THE ONSET OF FUTURE DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS**
 K. Gjeloshi, F. Danzo, G. Lettieri, G. Abignano, M. Hinton, A. Dean, G. Cuomo, O. Kubassova, F. Del Galdo
- P.232 EXAMINATION OF THE VALIDITY OF SKIN ULTRASOUND TO QUANTITATE SKIN INVOLVEMENT FOR MULTI-CENTER CLINICAL TRIALS IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC)**
 O. Aly, K. Kafaja, D. Furst
- P.233 NAILFOLD CAPILLAROSCOPY IN THE SPANISH GROUP OF SYSTEMIC AUTOIMMUNE DISEASES (GEAS). RESULTS OF AN ELECTRONIC SURVEY**
P. Fanlo, L. Saez, B. Gracia, M. Freire, Jose A. Todoli, B. Mari, G. Espinosa, F. Garcia, A. Guillén, N. Ortego, Juan J. Rios, A. Selva, V. Fonollosa
- P.234 FIRST PILOT STUDY OF T1 MAPPING MRI OF PERIPHERAL MUSCLE IN SYSTEMIC SCLEROSIS PATIENTS SHOWS DIFFUSE FIBROSIS THAT MAY ASSOCIATE WITH SUBCLINICAL CARDIAC INVOLVEMENT**
R. Dumitru, A. Goodall, David A. Broadbent, A. Kidambi, S. Plein, F. Del Galdo, A. Tan, J. Biglinds, M. Buch
- P.235 SEVERITY OF HAND VASCULAR INVOLVEMENT AS ASSESSED BY MRI DIGITAL ARTERY VOLUME INDEX (DAVIX®) PREDICTS WORSENING OF CLINICAL PARAMETERS AND PATIENT REPORTED OUTCOMES IN SCLERODERMA**
 F. Danzo, K. Gjeloshi, G. Lettieri, G. Abignano, M. Hinton, A. Dean, G. Cuomo, O. Kubassova, F. Del Galdo
- P.236 DEEP LEARNING FOR CALCINOSIS CUTIS QUANTIFICATION**
 A. Chandrasekaran, Z. Fu, A. Wang, S. Ren, R. Kraniski, I. Omar, M. Hinchcliff

IMAGING

- P.237** VISUALISATION OF THE ACTIVE CALCIFICATION PROCESS WITH 18-F SODIUM FLUORIDE PET/CT IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS WITH CALCINOSIS CUTIS IS FEASIBLE: A PILOT STUDY
G.M. Swart, I.M. Atzeni, E.M. Hogervorst, K. de Leeuw, M. Bijl, R. Bos, J. Westra, G.F. H. Diercks, H. van Goor, M.C. Bolling, R.H.J. A. Slart, [D.J. Mulder](#)
- P.238** CHANGE IN CALCINOSIS OVER 1 YEAR USING THE SCTC RADIOLOGIC SCORING SYSTEM FOR CALCINOSIS OF THE HANDS IN PATIENTS WITH SYSTEMIC SCLEROSIS
[V. Antonia](#), M. Chung, T. Rodriguez-Reyna, S. Proudman, M. Baron, F. Castolino, V. Hsu, S. Li, D. Fiorentino, K. Stevens, L. Chung
- P.239** COLOUR DOPPLER ULTRASONOGRAPHY IN DETECTION OF DIGITAL VASCULOPATHY IN SYSTEMIC SCLEROSIS
[O. Alekseeva](#), N. Yudkina, A. Volkov
- P.240** CROSS-VALIDATION AND COMPLEMENTARY VALUE OF OPTICAL COHERENCE TOMOGRAPHY AND HIGH FREQUENCY ULTRASOUND FOR THE ASSESSMENT OF SKIN DISEASE IN SYSTEMIC SCLEROSIS
[D. Temiz Karadag](#), G. Lettieri, V. Picerno, O. Gundogdu, M. Padula, G. Mennillo, A. Padula, F. Del Galdo, S. D'Angelo, G. Abignano
- P.241** RADIOLOGICAL HAND FINDING AND ITS CORRELATION WITH INTERNAL ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS
[N. Abdolahi](#), F. Badiiee, S. Tavassoli, M. Aghaei, M. Gharib, S. Livani

VASCULAR

- P.242** LATE ONSET (OVER 65 YEARS) RAYNAUD'S PHENOMENON MAY IDENTIFY A PECULIAR SYSTEMIC SCLEROSIS' SUBSET?
[L. Urso](#), F. Cacciapaglia, F. Montini, V. Venerito, S. Duma, F. Iannone
- P.243** THE CORRELATION BETWEEN CARDIOPULMONARY PARAMETERS AND ARTERIAL STIFFNESS IN A CROSS-SECTIONAL STUDY IN SYSTEMIC SCLEROSIS
[G. Szucs](#), M. Kalaszi, L. Bodoki, Z. Szekanez, S. Szamosi
- P.244** INFLUENCE OF EPOPROSTENOL INFUSIONS ON SERUM LEVEL OF ADIPOKINES IN SYSTEMIC SCLEROSIS
[A. Stochmal](#), J. Czuwara, M. Zaremba, L. Rudnicka
- P.245** SMOKING, RAYNAUD'S PHENOMENON, DIGITAL ULCERS AND SKIN THICKNESS IN THE WAIKATO SYSTEMIC SCLEROSIS COHORT
[K. Solanki](#), C. Silva, A. Schollum, D. White
- P.246** COPEPTIN AS A BIOMARKER OF PERIPHERAL MICROCIRCULATION DISORDERS IN SYSTEMIC SCLEROSIS
[M. Sikora](#), M. Chrabaszcz, M. Olszewska, L. Rudnicka
- P.247** WITHDRAWN
- P.248** SUBCLINICAL ATHEROMATOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS UNDER 60 YEARS OLD
I. Sanz Pérez, [A. Guillén-del-Castillo](#), F. Martínez-Valle, O. Orozco Gálvez, C. Marcos Fosch, E. Callejas-Moraga, M. Riveiro Barciela, M. Roca Herrera, P. Gubern Prieto, V. Fonollosa-Pla, C. Simeón-Aznar

- P.249** NAILFOLD CAPILLAROSCOPY FINDINGS IN MIXED CONNECTIVE TISSUE DISEASE
[B. Samões](#), D. Fonseca, R. Vieira, T. Videira, J. Abella-Aleixo, P. Pinto, M. Guerra
- P.250** A CANDIDATE GENE STUDY REVEALS ASSOCIATION BETWEEN A VARIANT OF THE SRP55 SPLICING FACTOR GENE AND SYSTEMIC SCLEROSIS (SSC)
E. Romano, M. Manetti, J. Kosalka, B. Fioretto, I. Rosa, E. Sticchi, S. Guiducci, S. Bellando-Randone, L. Ibba-Manneschi, [M. Mafucci-Cerinic](#)
- P.251** LINKING US AND EUROPE: CONSENSUS BASED STANDARD EVALUATION OF DERMATOSCOPY AND NAILFOLD VIDEOCAPILLAROSCOPY, A EULAR STUDY GROUP ON MICROCIRCULATION IN RHEUMATIC DISEASES PROJECT
[M. Radic](#), T. Frech, M. Snow, L. Saketkoo, M. Cutolo, V. Smith
- P.252** INCIDENCE OF PULMONARY ARTERIAL HYPERTENSION AND SCLERODERMA RENAL CRISIS IN SYSTEMIC SCLEROSIS PATIENTS WITH DIGITAL ULCERS ON ENDOTHELIN ANTAGONIST RECEPTORS AND PHOSPHODIESTERASE-5 INHIBITORS
[M. Pestana-Fernandez](#), M. Rubio-Rivas, C. Tolosa-Vilella, A. Guillén-Del-Castillo, M. Freire, J. Vargas Hitos, J. Todolí Parra, A. Marin Ballvé, D. Colunga Argüelles, C. González-Echávarri Pérez, N. Ortego-Centeno, L. Trapiella Martínez, X. Pla Salas, A. Chamorro, I. Perales Fraile, M. Ruiz Muñoz, E. Callejas Moraga, V. Fonollosa Pla, C. Simeón Aznar, On behalf of RESCLE Investigators
- P.253** DECREASED CAPILLARY DENSITY AND ALTERED CAPILLARY MORPHOLOGY IS ASSOCIATED WITH INTERNAL ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS
[G. Nagy](#), A. Kovács, T. Minier, C. Varjú, L. Czirájk, G. Kumánovics
- P.254** A PILOT STUDY OF PERFUSION AND OXYGENATION OF SYSTEMIC SCLEROSIS-RELATED DIGITAL (FINGER) ULCERS
[J. Manning](#), E. Marjanovic, T. Moore, G. Dinsdale, S. Wilkinson, M. Dickinson, A. Herrick, A. Murray
- P.255** PLASMA D-DIMER CONCENTRATION, MACROVASCULAR DISEASE AND MORTALITY IN PATIENTS WITH SYSTEMIC SCLEROSIS
[L. Montolio Chiva](#), J. Alegre Sancho, M. Robustillo Villarino, M. Aguilar Zamora, E. Valls Pascual, D. Ybañez Garcia, A. Martínez Ferrer, A. Orenes Vera, I. Vázquez Gómez, I. Torner Hernández, V. Nuñez Monje, A. Sendra Garcia
- P.256** LOWER-LIMB ULCERS IN SYSTEMIC SCLEROSIS: A MONOCENTRIC RETROSPECTIVE STUDY OF 16 PATIENTS
[E. Montabone](#), A. Penatti, V. Data, G. Gardini, P. De Nigris, R. Carignola
- P.257** SIGNIFICANCE OF ANGIOTENSIN II/ACE2/ANGIOTENSIN-(1-7) AXIS FOR THE PATHOGENESIS OF SYSTEMIC SCLEROSIS
[B. Miziolek](#), B. Bergler-Czop, E. Kucharz, P. Kotyla, M. Kopec-Medrek, M. Widuchowska, M. Sienczyk, A. Lupicka-Slowik, R. Grzywa, L. Brzezinska-Wcislo
- P.258** WITHDRAWN
- P.259** MICROPARTICLES IN SYSTEMIC SCLEROSIS: A PROMISING BIOMARKER OF MICROVASCULAR DAMAGE?
[S. Maximiano](#), I. Azevedo Teixeira, C. Nunes França, L. Garcia Biagi, M. De Oliveira Izar, C. Kayser

VASCULAR

- P.260** **DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (SSC) SERUM SIGNIFICANTLY IMPAIRS LYMPHANGIOGENESIS IN VITRO**
M. Manetti, E. Romano, I. Rosa, B. Fioretto, S. Guiducci, S. Bellando-Randone, E. Pigatto, F. Cozzi, L. Ibba-Manneschi, M. Matucci-Cerinic
- P.261** **THERMOGRAPHY OF THE TOES IN PATIENTS WITH SYSTEMIC SCLEROSIS AND RAYNAUD'S PHENOMENON**
R. Lim, J. Manning, T. Moore, S. Wilkinson, G. Dinsdale, A. Herrick
- P.262** **CLASSIFICATION OF FINGER PULP BLOOD FLOW AND ASSESSMENT OF RESISTANCE INDEX OF RADIAL ARTERY IN PATIENTS WITH SYSTEMIC SCLEROSIS AND HEALTHY CONTROLS**
A. Lescoat, A. Ballerie, F. Robin, M. De Saint Riquier, N. Belhomme, A. Perdriger, P. Jego, G. Coiffier, C. Cazalets
- P.263** **COMBINATION VASODILATOR THERAPY IMPROVES SKIN MICROVASCULAR BLOOD BUT DO NOT RESTORE ENDOTHELIAL FUNCTION IN SYSTEMIC SCLEROSIS**
C. Laurent, G. Harii, J. Laviglegrand, S. Riviere, J. Joffre, H. Ait Oufella, A. Mekinian
- P.264** **EPIGENETIC REGULATION MEDIATED REDUCTION IN THE EXPRESSION OF PROSTACYCLIN RECEPTOR (IP) AND PROSTACYCLIN SYNTHASE (PTGIS) IN SCLERODERMA SKIN, VASCULAR SMOOTH MUSCLE CELLS (VSMCS), AND MICROVASCULAR**
B. Kahaleh, Y. Wang, N. Altork
- P.265** **PREDICTORS OF NEW DIGITAL ULCERS IN SYSTEMIC SCLEROSIS; RESULTS FROM BEST-FITTED MODEL OF MULTIPLE REGRESSION ANALYSIS**
A. Javinani, F. Gharibdoost, A. Jamshidi, Z. Tamartash, H. Kavosi
- P.266** **EXPLORING PATIENTS' PERCEPTIONS AND BELIEFS ON DIGITAL ULCER PATHOGENESIS IN SYSTEMIC SCLEROSIS**
M. Hughes, J. Pauling, J. Jones, C. Denton, R. Domsic, T. Frech, A. Herrick, D. Khanna, M. Matucci-Cerinic, L. McKenzie, L. Saketkoo, R. Gooberman-Hill, A. Moore
- P.267** **DIGITAL ULCER DEBRIDEMENT IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW**
M. Hughes, B. Alcaccer-Pitarch, A. Gheorghiu, E. Praino, R. Sandler, Y. Tavor, C. Bruni, M. Matucci-Cerinic
- P.268** **A MULTI-CENTRE QUALITATIVE STUDY EXPLORING THE PATIENT EXPERIENCE OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS**
M. Hughes, J. Pauling, J. Jones, C. Denton, R. Domsic, T. Frech, A. Herrick, D. Khanna, M. Matucci-Cerinic, L. McKenzie, L. Saketkoo, R. Gooberman-Hill, A. Moore
- P.269** **EFFECT OF BIOFEEDBACK ON RAYNAUD'S SYNDROME IN SYSTEMIC SCLEROSIS PATIENTS**
R. Grekhoff
- P.270** **INVOLUNTARY WEIGHT LOSS AND BEING UNDERWEIGHT ARE INDEPENDENTLY ASSOCIATED WITH AN INCREASED RISK OF RAYNAUD'S PHENOMENON IN BOTH MEN AND WOMEN**
A. Eman Abdulle, S. Arends, H. van Goor, L. Brouwer, A. M. van Ron, J. Westra, A. Herrick, K. de Leeuw, D. J. Mulder

- P.271** **ELEVATED SERUM ENDOTHELIN -1 LEVELS IN PREECLAMPSIA ARE NOT ASSOCIATED WITH LONG-TERM MICROVASCULATURE DAMAGE AS EVALUATED BY NAILFOLD CAPILLAROSCOPY**
V. Dalm, J. Roeters Van Lennep, J. Duvekot
- P.272** **THE ROLE OF CANNABIDIOL OIL IN THE MANAGEMENT OF SYSTEMIC SCLEROSIS DIGITAL ULCER-RELATED PAIN**
L. Magnani, A. Spinella, E. Cocchiara, F. Lumetti, G. Bajocchi, C. Salvarani, D. Giuggioli
- P.273** **NEUTROPHIL TO LYMPHOCYTE RATIO AND MICROCIRCULATION IMPACT IN PATIENTS WITH SYSTEMIC SCLEROSIS – A CROSS-SECTIONAL STUDY**
V. Bernardino, A. Rodrigues, M. Fernandes, A. Lladó, A. Panarra
- P.274** **NON-SCLERODERMA CAPILLAROSCOPIC PATTERN IN PATIENTS WITH RAYNAUD'S PHENOMENON AND POSITIVE ANTIBODIES FOR SYSTEMIC SCLEROSIS**
V. Bernardino, A. Rodrigues, M. Fernandes, A. Lladó, A. Panarra
- P.275** **TREATMENT WITH INTRAVENOUS ILOPROST IN A MONOCENTRIC COHORT OF PATIENTS WITH SSC: COMPARISON BETWEEN TWO DIFFERENT THERAPEUTIC REGIMENS**
S. Barsotti, M. Di Battista, V. Venturini, S. Bilia, L. Puccetti, V. Lorenzoni, A. Della Rossa, G. Turchetti, M. Mosca
- P.276** **RAYNAUD'S PHENOMENON IN RHEUMATIC DISEASES: INCIDENCE AND CLINICAL MANIFESTATIONS**
Z. Bagautdinova, I. Gaisin
- P.277** **RAYNAUD'S PHENOMENON IN RHEUMATIC DISEASES AND PROSTANOID THERAPY WITH THE USE OF THE GENERALIZED INDICATOR OF RAYNAUD'S PHENOMENON MANIFESTATION**
Z. Bagautdinova, L. Gaisin, M. Giavatskikh
- P.278** **ASSOCIATION OF CAPILLAROSCOPIC ABNORMALITIES WITH THICKENING OF THE CAROTID BULB IN PATIENTS WITH SYSTEMIC SCLEROSIS: COMPARISON BETWEEN MICRO AND MACRO-CIRCULATORY CHANGES**
C. Angelelli, I. Sciarra, M. Vasile, K. Stefanantonio, G. Pellegrino, G. Valesini, V. Riccieri
- P.279** **HEMATOLOGICAL DISORDERS WITHIN SYSTEMIC SCLEROSIS: FREQUENCY AND CLINIC FEATURES**
B. Doskaliuk, R. Yatsyshyn

RENAL

- P.280** **CLINICAL FEATURES AND OUTCOME OF CHINESE PATIENTS WITH SCLERODERMA RENAL CRISIS: A CASE CONTROL STUDY**
J. Zhou, D. Xu, Y. Hou, Q. Wang, M. Li, X. Zeng
- P.281** **SCLERODERMA RENAL CRISIS IN THE RESCLE COHORT. ASSESSMENT OF PREDICTOR FACTORS AND CHANGE IN PREVALENCE OVER TIME**
X. Pla Salas, C. Tolosa Vilella, I. Pons Martín del Campo, E. Callejas Moragas, A. Guillén del Castillo, J. Todolí Parra, M. Rodríguez Carballera, A. Marín Ballvé, I. Perales Fraile, L. Sáez Comet, A. Argibay, A. Madroñero Vuelta, M. Sánchez García, C. González-Echavarrí, S. Sánchez Trigo, J. Sánchez-Redondo, R. Fernández de la Puebla G., V. Fonollosa Pla, C. Simeón Aznar, On behalf of RESCLE Investigators

RENAL

- P.282** **SCLERODERMA RENAL CRISIS OCCURS EARLY IN THE DISEASE COURSE: A CASE SERIES**
M. Joubert, L. Olagne, P. Smets, R. Outh, O. Aumaitre, C. Garrouste, A. Lautrette, M. Hermet, M. Andre
- P.283** **THE PATTERNS OF RENAL PATHOLOGY IN PATIENTS WITH SYSTEMIC SCLEROSIS RECEIVING RENAL BIOPSY: EXPERIENCE FROM A CHINESE TERTIARY MEDICAL CENTER**
X. Cao, Y. Hou, D. Xu, M. Li, Q. Wang, X. Zeng
- P.284** **SENSORY-MOTOR NEUROPATHY AND RENAL IMPAIRMENT IN A SYSTEMIC SCLEROSIS PATIENT: RARE BUT NOT SO RARE?**
K. Solanki, A. Schollum

MUSCULOSKELETAL SYSTEM & REHABILITATION

- P.285** **PSEUDOTUMORAL CALCINOSIS IN SYSTEMIC SCLEROSIS**
E. Zanatta, M. Desportes, D. Hoang, J. Avouac, F. Antoine, Y. Allanore
- P.286** **EFFICACY OF A TAILORED HAND/FACE REHABILITATION PROGRAM FOR SCLERODERMA PATIENTS: FINAL RESULTS OF A ONE-YEAR PROSPECTIVE CONTROLLED STUDY**
M. Spiritovic, H. Smucrova, S. Oreska, H. Storkanova, B. Hermankova, P. Cesak, A. Rathouska, O. Ruzickova, K. Pavelka, L. Senolt, J. Vencovsky, R. Becvar, M. Tomcik
- P.287** **CLINICAL CHARACTERISTICS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND SYMPTOMATIC SUBCUTANEOUS CALCINOSIS**
Y. Shirai, M. Kuwana
- P.288** **ASSESSING SKELETAL MUSCLE MASS WITH ULTRASOUND IN PATIENTS WITH SYSTEMIC SCLEROSIS**
A. Akdogan, A. Sari, M. Esme, L. Kilic, G. Aycecek, M. Halil
- P.289** **CLINICAL, PARACLINICAL AND RADIOLOGICAL ASSESSMENT OF THE MUSCULOSKELETAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS**
H. Poormoghim, N. Azarbari, A. Javadzadeh, E. Andalib, I. Mohseni, A. Jalali
- P.290** **PREVALENCE OF OSTEOPOROSIS IN SYSTEMIC SCLEROSIS - A POPULATION BASED STUDY**
K. Lilipers, I. Bartosik, D. Wuttge, K. Andréasson, K. Åkesson, R. Hesselstrand
- P.291** **PHYSICAL THERAPY IN SYSTEMIC SCLEROSIS: PERSPECTIVES FROM PATIENTS AND THEIR PHYSIOTHERAPISTS**
S. Liem, N. Van Leeuwen, E. Van Den Ende, L. De Punder, R. Schriemer, J. Spierings, M. Vonk, T. Vliet Vlieland, J. de Vries-Bouwstra
- P.292** **BONE MINERAL DENSITY AND TRABECULAR BONE SCORE ASSESSMENT IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY**
A. Lescoat, M. Leroy, G. Coiffier, C. Cazalets, N. Belhomme, A. Ballerie, F. Robin, P. Jegou, P. Guggenbuhl

- P.293** **THE EFFICACY OF A CONCISE SELF-MANAGEMENT PROGRAM FOR HANDS IN SSC – AN OBSERVATIONAL CASE-CONTROL STUDY**
S. Landim, M. De Barros Bértolo, Janet L. Poole, A. Del Rio, E. De Paiva Magalhães
- P.294** **MUSCULOSKELETAL MANIFESTATIONS OF SYSTEMIC SCLEROSIS: FOCUSING ON RIB OSTEOLYSIS**
J. Jun, J. Ryu, T. Kim, S. Lee
- P.295** **REDUCED CIRCULATING LEVELS OF INORGANIC PYROPHOSPHATE ARE ASSOCIATED WITH ECTOPIC CALCIFICATION IN SCLERODERMA SPECTRUM DISORDERS**
V. Hsu, N. Schlesinger, Q. Li, J. Varga
- P.296** **EFFECTS OF A HOME-BASED PULMONARY REHABILITATION PROGRAM, IN PATIENTS WITH INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSIS: A PILOT STUDY**
S. Faverzani, A. Ariani, A. Becciolini, F. Nocera, F. Mozzani, D. Santilli, L. Monica, L. Barone, V. Alferi, E. Crisafulli, M. Marvisi, M. Bigliardi, M. Tommasi, C. Micheli, L. Montinaro, G. Scopelliti, N. Salati
- P.297** **IF YOU DON'T USE IT, YOU LOSE IT': REHABILITATION OF FINGER DEXTERITY AND ABILITY TO PERFORM ACTIVITIES OF DAILY LIVING IN SYSTEMIC SCLEROSIS**
E. Eusterwiemann, M. Anderson, M. Robinson, Gabor J. Barton
- P.298** **SYSTEMIC SCLEROSIS OVERLAP SYNDROME IN 10 YEARS**
O. Desinova, M. Starovoytova, L. Ananieva
- P.299** **COMPARISON OF RELAPSING POLYCHONDritis PATIENTS WITH/ WITHOUT ARTHROPATHY ONSET**
X. Cao, Y. Hou, D. Xu, M. Li, Q. Wang, X. Zeng

GASTROINTESTINAL/NUTRITION

- P.300** **SEVERITY AND EVOLUTION OF GASTRO-INTESTINAL INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS IN TWO LARGE AND INDEPENDENT COHORTS**
N. Van Leeuwen, H. Fretheim, Ø. Molberg, T. Huizinga, J. De Vries-Bouwstra, A. Hoffman-Vold
- P.301** **METABOLITES DERIVED FROM GUT MICROBIOTA IN THE BLOOD OF PATIENTS WITH SYSTEMIC SCLEROSIS**
M. Sikora, A. Stec, M. Olszewska, L. Rudnicka
- P.302** **BODY COMPOSITION IN SCLERODERMA PATIENTS AND THE ASSOCIATION WITH THE DISEASE ACTIVITY, SYSTEMIC INFLAMMATORY CYTOKINES/CHEMOKINES, LIPID PROFILE AND NUTRITION STATUS**
S. Oreska, M. Spiritovic, P. Cesak, M. Cesak, H. Storkanova, H. Smucrova, B. Hermankova, O. Ruzickova, K. Pavelka, L. Senolt, J. Vencovsky, R. Becvar, M. Tomcik
- P.303** **SURVEY ON DYSPHAGIA USING SIMPLE QUESTIONNAIRE EAT-10 IN PATIENT WITH SYSTEMIC SCLEROSIS**
T. Naganawa, S. Yoshida, A. Kuwabara, M. Sawada, N. Watanabe, M. Suzuki, A. Umeda, K. Ashihara, M. Kurimizawa, D. Hirano, Y. Inamoto, T. Hashimoto, J. Nishino, S. Fukaya, S. Sibata, E. Saitoh, H. Yasuoka

GASTROINTESTINAL/NUTRITION

- P.304** ESOPHAGEAL INVOLVEMENT AND DETERMINANTS OF PERCEPTION OF ESOPHAGEAL SYMPTOMS AMONG EAST ASIAN PEOPLE WITH SYSTEMIC SCLEROSIS IN THE ERA OF HIGH-RESOLUTION MANOMETRY
H. Kim, W. Choi, M. Kim, T. Lee
- P.305** PREVALENCE OF GASTROESOPHAGEAL DISEASE IN SYSTEMIC SCLEROSIS AND ITS POTENTIAL IMPACT ON LUNG DISEASE
S. Kafaja, T. Shagrani, R. Saggar, A. Aly, I. Valera, P. Clements, J. Conklin, D. Furst
- P.306** PREDICTORS OF SIGNIFICANT WEIGHT LOSS IN SYSTEMIC SCLEROSIS - A STUDY FROM THE EULAR SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE
M. Hughes, C. Heal, J. Wilkinson, Eustar Investigators
- P.307** GASTROINTESTINAL INVOLVEMENT IS ASSOCIATED WITH DEPRESSION AND ANXIETY IN PATIENTS WITH SYSTEMIC SCLEROSIS
A. Gheorghiu, C. Vrancianu, B. Busuioc, C. Draganescu, A. Briceag, L. Macovei, M. Sasu, I. Ancuta, V. Stoica, M. Bojinca, C. Mihai
- P.308** RELATIONSHIP BETWEEN INTERSTITIAL PULMONARY DISEASE AND ESOPHAGIC PATHOLOGY IN SYSTEMIC SCLEROSIS. STUDY OF ONE COHORT OF 92 PATIENTS
P. Garcia De La Peña Lefebvr, G. González Arribas, M. Novella Navarro, J. González Martín
- P.309** MALNUTRITION IN SYSTEMIC SCLERODERMA: IS 'THE 15 PERCENT' RULE APPLICABLE?
A. Burlui, M. Graur, A. Gherasim, A. Cardoneanu, L. Macovei, E. Rezus
- P.310** GASTROPARESIS IN SYSTEMIC SCLEROSIS PATIENTS: CLINICAL CHARACTERISTICS
R. Brun, A. Balbir-Gurman, Y. Braun-Moscovici
- P.311** DURATION AND SYSTEMIC SCLEROSIS SUBTYPE ARE ASSOCIATED WITH DIFFERENT GUT MICROBIOME PROFILES
Y. Braun-Moscovici, S. Ben Simon, K. Dolnikov, S. Gieries, D. Markovits, Y. Tavor, K. Toledano, M. Nahir, A. Balbir-Gurman, O. Koren
- P.312** BIOELECTRICAL IMPEDANCE VECTOR ANALYSIS IN A COHORT OF PATIENTS WITH SSC AND IMPLICATION WITH CLINICAL ACTIVITY PARAMETERS
M. Di Battista, A. Rossi, S. Barsotti, A. Monaco, A. Della Rossa, M. Mosca
- P.313** SARCOPENIA IN PATIENTS WITH SYSTEMIC SCLEROSIS - PILOT STUDY FROM A SINGLE CENTER
M. Baresic, D. Ljubas Kelecic, B. Karanovic, I. Karas, Z. Krznaric, B. Anic
- P.314** SYSTEMIC SCLEROSIS AND VITAMIN D DEFICIENCY
L. Athanassiou, I. Kostoglou, E. Devetzi, M. Gatsiou, P. Tsakiridis, M. Mavroudi, A. Tzanavari, P. Athanassiou
- P.315** FEATURES OF DAMAGE OF THE GASTROINTESTINAL TRACT IN PATIENTS WITH SYSTEMIC SCLERODERMA
V. Aleksandrov, L. Shilova, A. Aleksandrov, I. Zborovskaya

GENDER RELATED ISSUES

- P.316** PREGNANCY OUTCOME IN SYSTEMIC SCLEROSIS; IS THERE ANY CORRELATION BASED ON TOPO I, DISEASE SUBTYPES AND DISEASE ONSET?
H. Poormoghim, M. Shakerian, E. Andalib, Z. Raufi, A. Jalali
- P.317** CLINICAL CHARACTERISTICS OF MALE PATIENTS WITH SYSTEMIC SCLEROSIS; RESULTS FROM IRANIAN SYSTEMIC SCLEROSIS REGISTRY
A. Javinani, F. Gharibdoost, A. Jamshidi, Z. Tamartash, M. Mahmoudi, H. Kavosi
- P.318** OBSTETRIC COMPLICATIONS PRIOR TO SYSTEMIC SCLEROSIS DIAGNOSIS
M. Chung, H. Zhao, K. Kolstad, P. Manwani, M. Dontsi, D. Postlethwaite, J. Simard, L. Chung
- P.319** ARE SILICON IMPLANTS ASSOCIATED SYSTEMIC SCLEROSIS (SSC) AND IDIOPATHIC SSC DIFFERENT ENTITIES?
Y. Braun-Moscovici, M. Braun, D. Markovits, K. Toledano, Y. Tavor, A. Rozin, K. Dolnikov, N. Finkelstein-Yeshurun, S. Gieries, M. Nahir, A. Balbir-Gurman
- P.320** FAVORABLE OUTCOME OF PLANNED PREGNANCIES IN SYSTEMIC SCLEROSIS PATIENTS DURING STABLE DISEASE
Y. Braun-Moscovici, D. Markovits, V. Shataylo, A. Avshalom-Mashiah, M. A. Nahir, A. Balbir-Gurman

RECENT ADVANCES IN THERAPY (CASE SERIES FOR NEW TREATMENT)

- P.321** THE EFFICACY AND SAFETY OF RITUXIMAB IN 27 CASES OF TREATMENT RESISTANT SYSTEMIC SCLEROSIS WITH SEVERE DISEASE: FAVORABLE EFFECT ON DISEASE ACTIVITY
Y. Yalcinkaya, B. Artim Esen, S. Amikishiyev, N. Aliyeva, A. Gul, L. Ocal, M. Inanc
- P.322** PREDICTIVE FACTORS FOR TREATMENT RELATED MORTALITY AND EVENT-FREE SURVIVAL AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: RESULTS OF A LONG TERM FOLLOW-UP MULTI-CENT
M. Vonk, S. Van Bijnen, M. Boonstra, E. Van Den Ende, L. Kroft, B. Geurts, M. Snoeren, A. Schouffoer, J. Spierings, J. van Laar, T. Huizinga, A. Voskuyl, W. van der Velden, F. van den Hoogen, J. de Vries-Bouwstra
- P.323** EFFECTIVENESS OF RITUXIMAB IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS. A MULTICENTER ANALYSIS
I. Vázquez Gómez, J. Lluch Pons, F. Narváez García, M. Aguilar Zamora, L. Montolio Chiva, A. Orenes Vera, E. Flores Fernández, A. Martínez Ferrer, E. Valls Pascual, D. Ybáñez García, I. Torner Hernández, V. Núñez Monje, A. Sandra García, J. Alegre Sancho
- P.324** AMINAPHTONE EFFICACY IS NOT INFLUENCED BY DIFFERENT PHARMACOLOGICAL BACKGROUNDS IN SYSTEMIC SCLEROSIS PATIENTS
A. Sulli, E. Gotelli, F. Goegan, B. Ruaro, C. Pizzorni, S. Paolino, M. Cutolo
- P.325** COMBINATION THERAPY OF RITUXIMAB AND MYCOPHENOLATE MOFETIL FOR SEVERE SYSTEMIC SCLEROSIS - SAFETY AND EFFICACY
D. Rimar, A. Silawi, I. Rosner, M. Rozenbaum, K. Kali, N. Boulman, G. Slobodin

RECENT ADVANCES IN THERAPY (CASE SERIES FOR NEW TREATMENT)

- P.326** **FIRST CASE OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS IN ESTONIA**
E. Pärsik, E. Raussj, D. Loigom, K. Palk, E. Ojassalu, P. Tuvik, Ä. Roose
- P.327** **RESPONSIVENESS TO CHANGE OF THE MODIFIED RODNAN SKIN SCORE IN A PHASE I/II DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL**
V. Nagaraja, E. Bush, R. Lafyatis, D. Khanna
- P.328** **COMPARISON OF SAFETY AND EFFICACY BETWEEN DIFFERENT BIOLOGIC THERAPIES IN SYSTEMIC SCLEROSIS**
D. Lobo-Prat, A. Millán, L. Sainz, H. Park, B. Magallares, P. Moya, S. Fernández, S. Ros, C. Diaz-Torné, A. Laiz, A. Garcia-Guillén, S. Jeria, H. Corominas, I. Castelli
- P.329** **STELLATE BLOCKADE COMBINED TO ILOPROST AS NEW TREATMENT OPTION FOR IMPROVEMENT OF ISCHAEMIC SYMPTOMS IN PATIENTS WITH SYSTEMIC SCLEROSIS – FIRST INTERIMS ANALYSIS OF A PROSPECTIVE OBSERVATIONAL STUDY**
F. Höcketsstaller, U. Henkemeier, M. Zimmermann, H. Burkhardt, F. Behrens, U. Drott, M. Köhm
- P.330** **BOTULINUM TOXIN: A PROMISING TREATMENT MODALITY FOR OROFASCIAL DIFFICULTIES IN SCLERODERMA PATIENTS**
S. Kafaja, P. Clements, D. Furst, D. Zinati, K. Omrani
- P.331** **THERAPY WITH RITUXIMAB IN SYSTEMIC SCLEROSIS (SSC): A SINGLE CENTRE COHORT STUDY**
I. Jandova, N. Venhoff, J. Thiel, C. Glaser, R. Voll
- P.332** **CHANGES IN ANTINUCLEAR ANTIBODY TITERS, ASSOCIATED WITH SYSTEMIC SCLEROSIS, DURING LONG-TERM RITUXIMAB THERAPY**
L. Garzanova, L. Ananyeva, O. Koneva, O. Ovsyannikova, O. Desinova, M. Starovoytova, S. Glukhova, M. Cherkasova, A. Alexankin
- P.333** **POSSIBLE BENEFIT OF TADALAFIL CREAM FOR THE TREATMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS**
A. Fernandez-Codina, M. Kazem, J. Pope
- P.334** **EFFECTS OF RITUXIMAB THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS**
M. Starovoytova, O. Desinova, L. Ananieva, L. Garsonova, O. Koneva, O. Ovsyannikova
- P.335** **EFFICACY OF SELEXIPAG ON DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: ANALYSIS OF A PRELIMINARY STUDY**
N. Del Papa, S. Bilia, D. Giannini, A. Grimaldi, E. Quarta, F. Pignataro, A. Minniti, W. Maglione, P. Migliorini, A. Tavoni
- P.336** **RITUXIMAB IN SYSTEMIC SCLEROSIS MANAGEMENT: MULTICENTRIC CLINICAL EXPERIENCE AND LONG-TERM FOLLOW-UP**
F. Lumetti, L. Magnani, A. Spinella, E. Cocchiara, G. Bajocchi, C. Ferri, C. Salvarani, D. Giuggioli

- P.337** **INTRAVENOUS IMMUNOGLOBULIN THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS: A MULTICENTER EXPERIENCE**
J. Tandaijan, A. Guillen, P. Carreira, F. Narváez, M. Rubio-Rivas, V. Ortiz-Santamaria, C. De La Puenta, J. Pego, R. García-Vicuña, A. Pros, C. Galisteo, B. Atienza-Mateo, J. Lluch, R. Blanco, C. Simeón-Aznar, I. Castellví
- P.338** **SAFETY AND EFFECTIVENESS OF ABATACEPT IN SYSTEMIC SCLEROSIS IN CLINICAL PRACTICE**
I. Castellví, M. Elhai, C. Bruni, P. Airó, S. Jordan, L. Beretta, V. Codullo, C. Montecuco, M. Bokarewa, F. Iannone, A. Balbir, V. Hsu, O. Distler, M. Matucci-Cerinic, Y. Allanore
- P.339** **SAFETY AND EFFICACY OF RITUXIMAB BIOSIMILAR IN SYSTEMIC SCLEROSIS: AN ITALIAN MULTICENTER STUDY**
C. Campochiaro, G. De Luca, M. Lazzaroni, E. Zanatta, S. Bosello, M. De Santis, A. Cariddi, C. Bruni, C. Selmi, E. Gremese, M. Matucci-Cerinic, A. Doria, P. Airó, L. Dagna
- P.340** **THE PHARMACOKINETICS OF MYCOPHENOLATE MOFETIL IN SYSTEMIC SCLEROSIS VARIES MANIFOLD BETWEEN PATIENTS AND IS ASSOCIATED WITH GASTROINTESTINAL INFLAMMATION**
K. Andréasson, K. Neringer, D. Henrohn, A. Mårtensson, D. Wuttge, R. Hesselstrand
- P.341** **EFFECTIVE ANTI-FIBROTIC THERAPY FOR SYSTEMIC SCLEROSIS: DUAL-TARGETING OF PERIPHERAL CANNABINOID-1 RECEPTORS AND INDUCIBLE NO SYNTHASE**
R. Cinar, J. K. Park, C. N. Zawatsky, J. Abdalla, M. Iyer, G. Kunos

PEDIATRIC SCLERODERMA

- P.342** **PROPOSAL OF OUTCOME MEASURES TO BE USED ON A 12-MONTH OPEN LABEL DRUG TRIAL IN JUVENILE SYSTEMIC SCLEROSIS. RESULTS OF THE 3RD CONSENSUS MEETING IN HAMBURG DECEMBER 2018**
I. Foeldvari, K. Torok, J. Anton, M. Blakley, T. Constantin, M. Curran, M. Cutolo, C. Denton, K. Figelstone, B. Heinrichs, A. Höger, F. Ingegnoli, S. Li, D. Nerncova, C. Orteu, C. Pilkington, V. Smith, A. Stevens, D. Khanna, D. Furst
- P.343** **NO DISEASE PROGRESSION AFTER 36 MONTHS FOLLOW UP IN THE JUVENILE SYSTEMIC SCLERODERMA INCEPTION COHORT**
I. Foeldvari, J. Klotsche, O. Kasapcopur, A. Adrovic, M. Terreri, R. Cimaz, T. Avcin, M. Katsikas, D. Nerncova, M. Santos, J. Brunner, T. Kallinich, M. Kostik, K. Minden, A. Patwardhan, K. Torok, N. Helmus
- P.344** **UNDER DETECTION OF INTERSTITIAL LUNG DISEASE IN JUVENILE SYSTEMIC SCLEROSIS (JSSC) UTILIZING PULMONARY FUNCTION TESTS. RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT**
I. Foeldvari, B. Hinrichs, K. Torok, M. Maria Jose, O. Kasapcopur, A. Adrovic, V. Stanevicha, F. Sztajnbock, M. Terreri, E. Alexeeva, J. Anton, M. Katsikas, V. Smith, T. Avcin, R. Cimaz, M. Kostik, T. Lehman, W.-A. Sifuentes-Giraldo, N. Helmus
- P.345** **HOW THE ADULT CRISS WORKS IN PEDIATRIC JSSC PATIENTS - RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT**
J. Klotsche, I. Foeldvari, O. Kasapcopur, A. Adrovic, K. Torok, V. Stanevicha, J. Anton, R. Cimaz, W.-A. Sifuentes-Giraldo, M. Terreri, F. Sztajnbock, C. Battagliotti, L. Berntson, D. Eleftheriou, G. Horneff, F. Nuruzzaman, N. Helmus

PEDIATRIC SCLERODERMA

- P.346** **IS THE PRESENTATION AND SEVERITY DIFFERENT OF THE JUVENILE DIFFUSE AND LIMITED SUBTYPE SYSTEMIC SCLEROSIS? RESULTS OF JUVENILE SCLERODERMA INCEPTION COHORT**
I. Foeldvari, J. Klotsche, O. Kasapcopur, A. Adrovic, K. Torok, V. Stanevicha, M. Terrier, F. Sztajn bok, E. Alexeeva, J. Anton, B. Feldman, M. Katsikas, V. Smith, T. Avcin, R. Cimaz, M. Kostik, T. Lehman, W.-Alberto Sifuentes-Giraldo, N. Vasquez-Canizares, N. Helms

SCLEROSING SKIN DISEASES (LOCALIZED SCLERODERMA)

- P.347** **A CASE REPORT OF MICROSURGICAL ALAR RECONSTRUCTION USING VASCULARIZED HELICAL RIM FLAPS FOR LOCAL SCLEROSIS PATIENT**
H. Xiao
- P.348** **LOW DOSE NALOXONE FOR THE MANAGEMENT OF PRURITUS IN PATIENTS WITH SCLERODERMA**
I. Vigdor chick, J. Berookhim, Y. Levy
- P.349** **SCLEREDEMA ADULTORUM OF BUSCHKE IS ASSOCIATED WITH A HIGHER PREVALENCE OF STROKE AND DYSLIPIDEMIA COMPARED TO DIABETICS WITHOUT SCLEREDEMA**
C. Varju, V. Csonka, B. Bódis, N. Farkas, D. Kovács, L. Czirják
- P.350** **COEXISTENCE OF SYSTEMIC SCLEROSIS AND MORPHEA**
A. Vanhaecke, L. Heeman, H. Callens, M. Cutolo, F. De Keyser, S. De Schepper, S. Nguyen, J. Guter muth, V. Smith
- P.351** **EFFECTIVENESS OF TOPICAL SODIUM TIOSULFATE FOR THE TREATMENT OF CALCINOSIS-ASSOCIATED CUTANEOUS ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS**
I. Torner Hernández, A. Sendra García, V. Nuñez Monje, L. Montolio Chiva, A.V. Orenes Vera, I. Vazquez Gomez, E. Flores Fernández, M. Aguilar Zamora, E. Vallis Pascual, A. Martinez Ferrer, D. Ybañez García, J. Alegre Sancho
- P.352** **CORRELATION OF EXPRESSION OF TLR7 AND MIRNA-146A GENES AND FIBROSIS IN PERIPHERAL BLOOD AND SKIN SAMPLES OF SSC PATIENTS**
V. Spasovski, M. Vreca, M. Andjelkovic, M. Stojijkovic, A. Skakic, K. Klaassen, A. Zekovic, N. Damjanov, S. Pavlovic
- P.353** **TOCILIZUMAB AS TREATMENT FOR CUTANEOUS INVOLVEMENT IN SYSTEMIC SCLEROSIS: A SERIES OF 3 CASES**
F. Ortiz-Sanjuán, C. Alcañiz, I. Cánovas, I. Chalmeta, M. De La Rubia, J. Fragio, R. González, L. González, E. Grau, S. Leal, I. Martínez, C. Nájera, R. Negueroles, C. Pávez, J. Oller, E. Vicens, J. Ivorra, J. Román-Ivorra
- P.354** **WITHDRAWN**
- P.355** **LOCO-REGIONAL TREATMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW**
I. Costedoat, M. Masson, T. Barnetteche, E. Lazaro, P. Duffau, C. Richez, J. Seneschal, M. Truchetet

- P.356** **ANALYSIS OF HISTOPATHOLOGICAL CUTANEOUS ALTERATIONS IN SYSTEMIC SCLEROSIS**
E. Cocchiara, A. Spinella, E. Veronesi, M. Pignatti, F. Lumetti, L. Magnani, G. Bajocchi, G. De Santis, C. Salvarani, M. Dominici, D. Giuggioli
- P.357** **EOSINOPHILIC FASCIITIS, A MONOCENTRIC RETROSEPTIVE STUDY OF 30 PATIENTS**
M. Thiebaut, B. Chaigne, N. Dupin, O. Mangin, P. Cohen, J. London, A. Regent, N. Costedoat-Chalumeau, C. Lejeunne, F. Authier, L. Mouthon
- P.358** **PROTEOMIC AND TRANSCRIPTOMIC ANALYSIS OF HUMAN EOSINOPHILIC FASCIITIS FIBROBLASTS**
B. Chaigne, C. Fernandez, M. Le Gall, P. Chafey, B. Saintpierre, V. Salnot, F. Guillonneau, C. Le Jeunne, L. Mouthon
- P.359** **CHARACTERIZATION OF SCLERODERMA PATIENTS ACCORDING TO RO52 AND KU ANTIBODIES**
J. Caballero Castro, A. Guillén Del Castillo, E. Callejas Moraga, D. Colunga Argüelles, L. Sáez Comet, M. Rubio Rivas, A. Argibay, J. Vargas Hitos, J. Todolí Parra, I. Perales Fraile, C. Tolosa Vilella, A. Marin Ballvé, A. Madroñero Vuelta, M. Sánchez García, N. Ortego-Centeno, G. Espinosa, M. Rodríguez Carballeira, V. Fonollosa Pla, C. Simeón Aznar, On behalf of RESCLE Investigators
- P.360** **POTENTIAL BIOMARKERS OF SKIN CHANGES IN SYSTEMIC SCLEROSIS**
R. Becvar, H. Storkanova, B. Sumova, M. Spiritovic, S. Oreska, L. Senolt, M. Tomcik
- P.361** **PREVALENCE AND ASSOCIATES OF CANCER IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS ATTENDING A SINGLE CENTRE**
A. Agnihotri, J. Manning, S. Wilkinson, M. Samaranyaka, A. L. Herrick

EMERGING THERAPIES (PRE-CLINICAL)

- P.362** **AN ORALLY AVAILABLE HIGHLY SELECTIVE 5-HYDROXYTRYPTAMINE 2B (5-HT2B) RECEPTOR ANTAGONIST AMELIORATING PULMONARY AND DERMAL FIBROSIS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS**
H. Arozenius, L. Pettersson, G. Ekström, C. Wenglé
- P.363** **HSP90 INHIBITOR 17-DMAG REDUCES PROGRESSION OF DERMAL FIBROSIS AND INDUCES REGRESSION OF ESTABLISHED EXPERIMENTAL DERMAL FIBROSIS IN MICE INDUCED BY BLEOMYCIN**
H. Storkanova, L. Storkanova, S. Oreska, M. Spiritovic, B. Hermankova, R. Becvar, K. Pavelka, J. Vencovsky, J. Distler, L. Senolt, M. Tomcik
- P.364** **VITAMIN D DOWNREGULATES PRO-FIBROTIC MOLECULES ASSOCIATED WITH SYSTEMIC SCLEROSIS: ALPHA-SMA AND PSMAD2/3**
A. Rodrigues De Almeida, M. De Oliveira Gonçalves, E. Gustavo Constantino Cunha, J. De Melo Gomes, A. Tavares Dantas, R. Silva Guimarães Gonçalves, A. Luzia Branco Pinto Duarte, M. Barreto De Melo Régo, M. Cristiny Pereira, M. D. Lima De Oliveira, M. Galdino Da Rocha Pitta
- P.365** **CADHERIN 11 AND COLLAGEN I IN A SCLERODERMA FIBROTIC MODEL AND EFFECT OF MECHANOSENSING AND INFLAMMATORY INHIBITORS ON THEIR EXPRESSION**
A. Mujkanovic, T. Lim, X. Shiwen, B. Ahmed Abdi, G. Martin, H. Lopez, D. Abraham, C. Denton, R. Stratton

EMERGING THERAPIES (PRE-CLINICAL)

- P.366** **VASCULARIZED HUMAN SKIN EQUIVALENTS AS A NOVEL IN VITRO MODEL OF SKIN FIBROSIS AND PLATFORM FOR TESTING OF ANTIFIBROTIC DRUGS**
A. Matei, C. Chen, L. Kiesewetter, A. Györfi, Y. Li, T. Trinh-Minh, X. Xu, T. Cuong, Toin H. Van Kuppevelt, J. Hansmann, A. Jüngel, G. Schett, F. Groeber-Becker, J.H.W. Distler
- P.367** **IMPACT OF JAK INHIBITORS ON MACROPHAGE POLARISATION: PERSPECTIVES FOR SYSTEMIC SCLEROSIS**
A. Lescoat, A. Ballerie, M. Lelong, C. Morzadec, S. Jouneau, P. Jego, L. Vernhet, O. Fardel, V. Lecureur
- P.368** **SECUKINUMAB AND METFORMIN AMELIORATE BLEOMYCIN INDUCED DERMAL FIBROSIS**
 C. Celik, A. Karatas, B. Oz, Z. Akar, E. Etem, A. Dagli, S. Koca
- P.369** **BOTULINUM TOXIN IN THE MANAGEMENT OF RAYNAUD'S PHENOMENON**
D. Ennis, Z. Ahmad, K. Devakandan, M. Anderson, S. Johnson
- P.370** **TRAINED IMMUNITY MODULATES INFLAMMATION-INDUCED FIBROSIS**
M. Jeljeli, L. Gama Coelho Riccio, L. Doridot, C. Chêne, C. Nicco, S. Chouzenoux, Q. Deletang, Y. Allanore, N. Kavian, F. Batteux
- P.371** **2-CARBA-CPA AMELIORATES EXPERIMENTAL DERMAL FIBROSIS BY SUPPRESSING THE ACTIVATION OF FIBROBLASTS AND IMMUNE CELLS**
T. Higuchi, K. Takagi, A. Tochimoto, T. Norose, I. Masuda, T. Sawada, N. Shibata, T. Morohoshi, M. Harigai, Y. Kawaguchi
- P.372** **INHIBITION OF IL-4 AND IL-13 PRODUCTION BY A NEW THIAZOLIDINE DERIVATIVE (SF-34) IN PBMC FROM SYSTEMIC SCLEROSIS PATIENTS**
M. Galdino Da Rocha Pitta, A. Rodrigues De Almeida, A. Tavares Dantas, E. Gustavo Constantino Cunha, M. Bezerra Correia, L. De Azevedo Valadares, M. De Oliveira Gonçalves, J. De Melo Gomes, M. Barreto De Melo Rêgo, I. Da Rocha Pitta, M. Galdino Da Rocha Pitta, A. Luzia Branco Pinto Duarte, D. Saes Parra Abdalla
- P.373** **CXCL5 AMELIORATES SYSTEMIC SCLEROSIS VIA SUPPRESSING HELPER T CELL-MEDIATED IMMUNE RESPONSE**
X. Fan, D. Guo, C. Ng, A. Law, K. Lim, J. Thumboo, W. Hwang, A. Low
- P.374** **ADIPOSE-DERIVED MESENCHYMAL STEM CELLS CONDITIONED MEDIUM INHIBITS PRO-FIBROTIC ACTIVITY OF SSC FIBROBLASTS AND INDUCE A PRO-ANGIOGENIC PHENOTYPE**
N. Del Papa, M. Lorini, V. Carbonelli, F. Pignataro, A. Minniti, F. Campanaro, C. Verrastro, W. Maglione
- P.375** **PED5 INHIBITOR SILDENAFIL COUNTERACTS THE DNA DAMAGE INDUCED BY OXIDATIVE STRESS IN SCLERODERMA FIBROBLASTS**
 L. Di Luigi, G. Duranti, A. Antonioni, P. Sgro', R. Ceci, D. Caporossi, S. Sabatini, F. Del Galdo, A. Lenzi, I. Dimauro, C. Antinozzi
- P.376** **CONSTITUTIVE ACTIVATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 IN LUNG AND SKIN OF TRANSGENIC MOUSE - A NEW MODEL OF SCLERODERMA**
G. Bogatkevich, I. Atanelishvili, T. Akter, A. Bogatkevich, R. Silver

CASE REPORTS

- P.377** **NEWLY DIAGNOSED SYSTEMIC SCLEROSIS IN AFRICAN PATIENT DURING VISIT IN SWEDEN – ETHICAL DILEMMAS OF MEDICAL CARE AND FOLLOW-UP**
E. Thomaïdi
- P.378** **A RARE PRESENTATION OF RENAL IMPAIRMENT IN DIFFUSE SYSTEMIC SCLEROSIS PATIENT**
K. Solanki, A. Schollum, D. Lamont, D. White
- P.379** **EXTENSIVE CALCINOSIS CUTIS IN A PATIENT WITH SYSTEMIC SCLEROSIS**
T. Simopoulou, M. Vlychou, D. Bogdanos, L. Sakkas
- P.380** **GAVE - AN OFTEN OVERLOOKED COMPLICATION IN SYSTEMIC SCLEROSIS**
R. Shukla, A. Herrick
- P.381** **THE RENAL CRISIS CONUNDRUM**
S. Shoela, A. Beltagy
- P.382** **PERICARDIAL INVOLVEMENT AND CREST SYNDROME**
O. Selmi, I. Saoud, M. Lajmi, I. Chaabane, R. Amri, H. Tounsi, W. Garbouj, B. Ben Ammou, J. Ouali, R. Jazi
- P.383** **A CASE OF SYSTEMIC SCLEROSIS & NEUROSARCOIDOSIS**
A. Schnell, A. Gaffo
- P.384** **GRANULOMATOUS UVEITIS REVEALING SCLEROMYOSITIS**
I. Saoud, W. Garbouj, O. Selmi, R. Amri, H. Tounsi, M. Lajmi, I. Chaabane, Z. Alaya, B. Ben Ammou, J. Ouali, R. Jazi
- P.385** **SYSTEMIC SCLEROSIS – A POLYSEGMENTAL REFLEX DYSTROPHY – TREATED BY MATRIX RHYTHM THERAPY. CASE REPORT SEVEN YEARS AFTER DIAGNOSIS**
 U. Randoll, Y. Largiadere
- P.386** **SEVERE AORTIC ROOT DILATATION IN PSS REVERSING WITH AGGRESSIVE MEDICAL THERAPY**
C. Rajapakse
- P.387** **SYSTEMIC SCLEROSIS INDUCED BY CNS STIMULANTS FOR ADHD: A CASE SERIES AND REVIEW OF THE LITERATURE**
K. Meridor, Y. Levy
- P.388** **AN UNUSUAL EOSINOPHILIC FASCITIS OCCURRING IN A FITNESS TRAINER: COINCIDENCE OR RELATIONSHIP?**
E. Meleddu, F. Renzullo, P. Mascia, A. Cauli, A. Vacca
- P.389** **SYSTEMIC SCLEROSIS AND NEPHROTIC SYNDROME: AN UNUSUAL ASSOCIATION**
P. Martins, E. Dourado, F. Marques, S. Jorge, J. Lopes, J. Guerra, J. Fonseca, I. Cordeiro, C. Resende
- P.390** **A CASE REPORT OF SYSTEMIC SCLERODERMA WITH POSITIVE ANTI-KU AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES**
M. Lajmi, I. Saoud, O. Selmi, H. Tounsi, I. Chaabane, W. Garbouj, Z. Alaya, B. Ben Ammou, R. Jazi, O. Jihen, R. Amri

CASE REPORTS

- P.391** **SYSTEMIC SCLEROSIS ASSOCIATED WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE**
J. Jung, S. Choi, G. Song
- P.392** **SEVERE LIMB ISCHEMIA AFTER VASOPRESSOR THERAPY DUE TO SEPTIC SHOCK FROM PERFORATED ACALCULOUS CHOLECYSTITIS IN A PATIENT WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS**
J. Jun, J. Kang, Y. Kim
- P.393** **SYSTEMIC SCLEROSIS SKIN CHANGES AND MULTI-ORGAN INVOLVEMENT AFTER TAXANE TREATMENT**
N. Bakhsh, K. Devakandan, Z. Ahmad
- P.394** **SUDDEN CARDIAC DEATH IN TWO PATIENTS WITH RAPIDLY PROGRESSING SYSTEMIC SCLEROSIS**
R. Izzo, G. Pellegrino, G. Olivieri, C. Angelelli, K. Stefanantoni, C. Perricone, C. Alessandri, R. Scrivo, F. Conti, R. Priori, G. Valesini, V. Ricciari
- P.395** **RARE PULMONARY MANIFESTATIONS OF SYSTEMIC SCLEROSIS – A UNIQUE CASE OF DIAPHRAGMATIC DYSFUNCTION**
M. Guerra, M. Silva, S. Neves, B. Samões, D. Fonseca, T. Videira, R. Vieira, J. Abelha-Aleixo, P. Pinto
- P.396** **WITHDRAWN**
- P.397** **DEPLETION OF B-CELLS IN PERIPHERAL BLOOD FOR 10 YEARS IN A PATIENT WITH SYSTEMIC SCLEROSIS, AFTER A SINGLE INFUSION OF RITUXIMAB**
L. Garzanova, L. Ananyeva, O. Koneva
- P.398** **SYSTEMIC SCLEROSIS TRIGGERED BY CHIKUNGUNYA FEVER**
S. Fontenele, I. Barbosa, B. Parente, J. Monte, M. Moura
- P.399** **GROUP 3 OR COMBINED GROUP 1 AND GROUP 3 PULMONARY HYPERTENSION? THREE CASES WITH THREE SCENARIOS**
S. Erol, Z. Onen, O. Ozdemir Kumbasar, T. Sayin, C. Tulunay Kaya
- P.400** **MORPHEA WITH ASSOCIATED SYSTEMIC MANIFESTATIONS: A CASE REPORT**
A. Elsonbaty, N. Adel Abbas, N. Fathi
- P.401** **INDUCED SCLERODERMA**
V. Babak, M. Starovoytova, O. Desinova, L. Ananieva
- P.402** **SCLEROMYXEDEMA WITH MULTIPLE SYSTEMIC INVOLVEMENT: INTRAVENOUS IMMUNOGLOBULIN AS STEROID-SPARING AGENT**
W. Choi, S. Kim, K. Lee, H. Kim
- P.403** **WHY THE SCLERODERMIFORM AFFECTIONS ARE CONSIDERED BORING DISEASES**
G. Chalhoub
- P.404** **TOFACITINIB IS A THERAPEUTIC OPTION FOR REFRACTORY EOSINOPHILIC FASCITIS**
X. Cao, J. Zhao, Y. Hou, D. Xu, M. Li, Q. Wang, X. Zeng
- P.405** **ACR/EULAR 2013 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS: AN EXAMPLE OF FEMALE PATIENT WITH EARLY FORM OF SCLERODERMA DIAGNOSED AT CHILDHOOD**
K. Bouchalova, P. Horak, D. Pospisilova
- P.406** **DILTIAZEM-INDUCED MYOSITIS IN A PATIENT WITH SYSTEMIC SCLEROSIS**
S. Berthier, A. Grandvullemin, B. Nicolas, A. Guilhem, V. Leguy, M. Samson, S. Audia, B. Bonnotte
- P.407** **MALIGNANCY IN A SINGLE CENTER COHORT OF SYSTEMIC SCLEROSIS PATIENTS**
A. Balbir Gurman, V. Shataylo, A. Mashiah, N. Schultz, E. Sabbah, Y. Tavor, M. Nahir, K. Dolnikov, N. Finkilstein, Y. Braun-Moskovic
- P.408** **IGG-4 RELATED AORTITIS IN A PATIENT WITH RA-SSC OVERLAP, AN UNEXPECTED COMBINATION**
A. Balbir Gurman, Y. Tavor, L. Guralnik, Y. Braun-Moskovic
- P.409** **DRAMATIC SCLERODERMA DEBUT WITH MALIGNANT HYPERTENSION AND RENAL CRISIS**
A. Balbir Gurman, G. Milo, S. Assady, R. Dragu, K. Dolnikov, Y. Braun-Moskovic

ACCELERATING DRUG DISCOVERY TO TRANSFORM PATIENTS' LIVES

Acceleron Pharma Inc.
128 Sidney Street
Cambridge, MA 02139
www.acceleronpharma.com

©2020 Acceleron Pharma Inc.
All rights reserved.



ACKNOWLEDGEMENTS

The Congress Organisers gratefully acknowledge support received from all exhibitors and the following sponsors:

PLATINUM SPONSORS



GOLD SPONSORS



SILVER SPONSORS



OTHER





Organizing Secretariat



AIM Group International

Florence Office

Viale G. Mazzini, 70

50132 Florence, Italy

ph. +39 055 233881

fax +39 055 2480246

ssc2020@aimgroup.eu

www.worldsclerofound.org